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Forget the great human heart and brain, the eyes that see sweeping vistas, the lips 
that declare “I am”. The real thing standing between us and the primordial ooze is 
the human skeleton. Built of 206 bones, the skeleton is a living cathedral of ivory 
vaults, ribs and buttresses – a structure at once light and strong, flexible and firm. 
 
Angier, N.  
New York Times November 1994 
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NORSK SAMMENDRAG 
 
Beinskjørhet (osteoporose) er en forstyrrelse i skjelettstoffskiftet som gir økt beintap, redusert 
beinoppbygning og dermed mindre beinvev. Dette øker risikoen for beinbrudd, og hvert år 
pådrar over 25 000 nordmenn seg såkalte lavenergibrudd – som hoftebrudd, underarmsbrudd 
og brudd i ryggen forårsaket av et traume som hos beinfriske ikke ville medført skade. 
Folkehelseinstituttet har estimert at hoftebrudd alene koster samfunnet ca. 2 millarder NOK 
årlig og for den enkelte kan et slikt brudd være fatalt; ca 25 % av eldre med lårhalsbrudd dør i 
løpet av det første året etter bruddet. Vi vet mye om hvilke faktorer som øker risikoen for 
osteoporose, imidlertid er det fremdeles uavklarte molekylære mekanismer bak denne vanlige 
lidelsen. Det er derfor både i den enkelte pasients og samfunnets interesse at kunnskapen om 
de molekylære mekanismene ved osteoporose økes, slik at vi kan utvikle bedre behandling og 
ikke minst kunne forutse og forebygge osteoporose og lavenergibrudd.  
I det første arbeidet i avhandlingen ”Experimental studies on bone with focus on tartrate-
resistant acid phosphatase and bone remodeling” har cand.med. Lene B. Solberg og 
medarbeidere studert sammenhengen mellom osteoporose og bruddtilheling hos rotte. Ved å 
måle beintetthet og mekaniske egenskaper til bruddområdet under tilheling fant gruppen ingen 
forskjeller mellom osteoporotiske og normale dyr, og konkluderer med at brudd hos 
osteoporotiske rotter gror som normalt. I de to påfølgende arbeidene har Solberg og 
medarbeidere studert enzymet tartrate-resistant acid phosphatase (TRAP) som blant annet 
produseres og skilles ut fra beinnedbrytende celler (osteoklaster). En beinspesifikk type av 
TRAP (TRAP 5b) kan måles i serum og flere studier har vist at mengden TRAP 5b i serum er 
direkte proporsjonal med osteoklastantallet og har prognostisk og diagnostisk verdi i 
kartlegging av osteoporose. Imidlertid er TRAPs direkte rolle i beinstoffskiftet ukjent. Solberg 
og medarbeidere har brukt rotter med osteoporose og D-vitaminmangelsykdom samt unge 
rotter i vekst til å studere omsetningen av TRAP i beinvev. Ved hjelp av ulike lys- og 
elektronmikroskopiske teknikker fant gruppen økt nivå av TRAP i flere typer beinceller 
(osteoblaster og osteocytter) hos osteoporotiske rotter. Gruppen fant TRAP sammen med en 
faktor som regulerer beinnedbrytningen (RANKL) og som skilles ut fra osteoblaster og 
ostecytter. Disse nye funnene taler for at TRAP kan ha flere oppgaver i bein, og gruppen 
foreslår at TRAP har en rolle i reguleringen av beinnedbrytningen og/eller er et signalmolekyl 
i koblingen mellom beinnedbrytning og beinoppbygging.  
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1 INTRODUCTION 
The bony skeleton is an organ constantly being changed and rebuilt in order to maintain its 
structural and metabolic functions. It provides body support critical for locomotion, 
respiration and protection of the internal organs as well as houses the bone marrow and 
sharing cells and local regulatory factors with the hematopoietic system. The bone tissue 
components include the mineralized and un-mineralized connective tissue matrix, bone cells 
and water and serve as an ion reservoir, crucial for the calcium and phosphate homeostasis in 
blood. The importance of studying skeletal physiology and pathology is illustrated by the 
incidence of bone diseases affecting the various skeletal functions such as the control and 
arrest of skeletal longitudinal growth, bone mineralization and control of bone mass 
manifested i.e. as dwarfism, rickets and osteoporosis as well as some less prevalent diseases 
such as osteogenesis imperfecta and sclerostosis.  
 
1.1 Bone biology 
Newborn and infants have between 300-350 bones which fuse at different time-points during 
skeletal maturation and growth to the 206 bones making up the adult skeleton. The axial 
skeleton comprises the bones in the midline (skull bones, hyoid bone, vertebrae, sternum and 
ribs) while the appendicular skeleton includes the extremities, scapulas, clavicles and pelvis. 
The individual bones can be further classified depending on their gross appearance and 
architectural structure; most bones of the appendicular skeleton (such as femur and tibia) are 
long bones (Fig. 1), whereas flat bones are found in the skull, mandible, scapula and pelvis. 
Cortical bone makes up the dense outer shell of all bones and the diaphysis of long bones 
providing mechanical strength and protection, while cancellous bone is found in the center of 
flat bones and underneath the cortical shell as well as in the metaphysis of long bones. 
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Modified images from Wikimedia Commons, the free media repository; 
http://commons.wikimedia.org/wiki/File:Illu_long_bone.jpg; 
http://commons.wikimedia.org/wiki/File:Illu_compact_spongy_bone.jpg 
 
Fig. 1 The anatomy of long bones The epiphyses, metaphyses and diaphysis in humerus with 
the insert showing details of the cortical and cancellous bone. Cortical bone, comprises 80% 
of the skeletal weight, is compact with tightly packet lamellae or osteons characterized by 
collagen fibers oriented axial to the applied mechanical force wrapped around a central 
(Haversian) canal which contains blood and lymphatic vessels and nerves. The vessels enter 
bone from the periosteum or the bone marrow through Volkmann’s canals running 
perpendicular to the Haversian canals. Cancellous bone has a “spongy” appearance with thin 
bony plates (trabeculae) forming a complex network hosting the bone marrow. A high 
surface-to-volume ratio and close relation to the circulation enable cancellous bone to play a 
key role in the circulating calcium and phosphate homeostasis. The endosteum is a thin 
delicate membrane of osteogenic cells lining the bone adjacent to the bone marrow, while the 
outer surface is covered with the periosteum (except for where it’s coated with articular 
cartilage) serving as attachment for ligaments and giving rise to the osteogenic cells. 
 
1.1.1 Bone development and growth 
The embryonic bone tissue develops from condensations of mesenchymal cells and is formed 
either directly by differentiation of the mesenchymal cells into bone-forming osteoblasts 
(intramembranous ossification); or in a multi-level process designated endochondral 
ossification where cartilaginous structures are built, resorbed and replaced by bone (Fig. 2). 
Intramembranous bone formation occurs in the skull, part of the facial bones and clavicles in 
addition to the periosteal column of long bones, whereas endochondral bone formation occurs 
in the rest of the axial and appendicular skeleton. The embryonic bone enlarges by 
appositional growth, while the epiphyseal growth plate enables continued elongation of long 
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bones through chondrocyte proliferation and hypertrophy as long as the growth plate exists. 
At the time of puberty, sex hormone levels increase leading to a phase of accelerated bone 
growth followed by closure of the epiphyseal growth plates. Although longitudinal growth of 
long bones ceases after puberty, bone formation continues in an appositional manner via 
intramembranous bone formation in the diaphysis increasing the transverse diameters of the 
long bones.  
 
From: Diseases of bone and mineral metabolism, Singer F (Ed). Copyright © 2008 
WWW.ENDOTEXT.ORG Reproduced with permission from Dr. Roland Baron. 
 
Fig. 2 Endochondral ossification The mesenchymal cells condensate and differentiate into 
chondrocytes producing a cartilage template. The cells at the border form the perichondrium 
which transforms into the periosteum and the bone collars which become the future cortical 
bone. The chondrocytes in the center hypertrophy and mineralize their surroundings, and 
attract capillaries, osteoblasts and chondroclasts/osteoclasts to the mineralized cartilage before 
they die. The invading cells form the primary ossification center where osteoblasts synthesize 
immature (woven) bone upon the cartilage remnants becoming the future cancellous bone. As 
the bone grows, the central part is gradually resorbed and populated with myeloid stromal 
cells establishing the main site of the hematopoiesis in post-natal life. Secondary ossification 
centers (SOCs) develop (usually after birth) in the same manner as the primary centers. In 
long bones, SOCs are formed in the epiphysis leaving only a cartilaginous growth plate 
between the primary and secondary ossification centers.  
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1.1.2 The epiphyseal growth plate 
When secondary ossification (Fig. 2) is complete, the cartilage model is totally replaced by 
bone except for in two areas; a region of articular cartilage remains at the distal end of the 
epiphysis as well as a transverse disc of cartilage between the epiphysis and the diaphysis 
called the epiphyseal growth plate. The growth plate contains chondrocytes at different stages 
of development, and proliferation and differentiation of these cells provide elongation of the 
long bones (Fig. 3).  
 
 
 
Fig. 3 The epiphyseal growth plate Light microscopic image from a 10 weeks old normal 
male rat. The growth plate can be divided into 3 zones; the resting zone (RZ), the proliferative 
zone (PZ) and the hypertrophic zone (HZ) next to the primary spongiosa (PS) - the initial 
trabecular network remodeled into cancellous or cortical bone. The cartilaginous cells 
proliferate as long as the growth plate exists. However, the epiphyseal disc does not increase 
in thickness as the cartilage matures and mineralizes because the cartilage is resorbed and 
replaced by primary spongiosa at the same speed in a tightly controlled manner. Scale bar 
100μm 
 
1 INTRODUCTION 
5 
 
1.1.3 Regulation of chondrogenesis 
The chondrogenesis in both embryonic and post-natal endochondral bone formation is strictly 
regulated to ensure normal longitudinal bone growth. The differentiation of condensated 
mesenchymal cells into chondrocytes is crucial for the development of the cartilaginous 
model. The differentiation is driven by cell-extracellular matrix (ECM) and cell-cell adhesion 
interactions mediated by hormonal and local factors controlling the key transcription factors 
SOX9 and RUNX2. SOX9 is one of the earliest markers of the chondrocyte lineage and 
crucial for the differentiation of condensated mesenchymal cells into chondrocytes, while 
RUNX2 is the main inducer of hypertrophic differentiation and is expressed by 
prehypertrophic and hypertrophic chondrocytes. Members of the WNT family regulate 
chondrocyte differentiation from mesenchymal precursor cells (MPC) via chondrocytes to 
hypertrophic chondrocytes in different ways; e.g. WNT5a and 5b (non-canonical pathways) 
stimulate differentiation from MPC to mature chondrocytes. Loss of β-catenin activity is 
required in mesenchymal cells to permit chondrocyte differentiations, but inhibits further 
differentiation into hypertrophic chondrocytes (reviewed in [2-4]). The Indian hedgehog 
protein (IHH) is expressed in prehypertrophic chondrocytes and is required for normal 
chondrocyte proliferation as well as coupling the chondrocyte hypertrophy with 
osteoblastogenesis by signaling to the adjacent perichondrium to induce osteoblast 
differentiation. IHH also induces PTH (parathyroid hormone)-related peptide (PTHrP) in 
articular cartilage and periarticular cells (chondrocytes in the distal ends of the condensation). 
The PTH/PTHrP receptor (PPR1) is expressed at much higher levels in the proliferating and 
prehypertrophic chondrocytes, and activation of PPR1 prevents the onset of hypertrophic 
differentiation and thus the differentiation of IHH expressing cells. This forms a negative 
feedback-loop controlling the proliferating chondrocytes (reviewed in [2, 3]). IHH expression 
is promoted by bone morphogenic proteins (BMPs) and stimulates chondrocyte proliferation, 
while the fibroblast growth factors (FGFs) inhibit proliferation. Circulating hormones also 
play a crucial role in controlling the growth and inhibitory factors secreted by the 
chondrocytes during the different stages of differentiation (reviewed in [5]); e.g. growth 
hormone (GH) from the pituitary gland stimulates the secretion of insulin-like growth factor 1 
(IGF-1) necessary for both chondrocyte proliferation and hypertrophy; thyroid hormone-
induced hypertrophy appears to be mediated through the WNT/β-catenin (canonical) pathway. 
In addition to limiting the proliferation rate, the hypertrophic chondrocytes regulate cartilage 
mineralization by releasing matrix vesicles to the surrounding ECM [6, 7] providing the 
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nucleation site for mineralization. The hypertrophic chondrocytes also regulate the invasion of 
vessel-forming cells, chondroclasts/osteoclasts as well as osteoblasts to the mineralized 
cartilage by expressing vascular endothelial growth factor (VEGF) promoting the vascular 
invasion, high-mobility group box 1 protein (HMGB1) acting on endothelial cells, osteoblasts 
and osteoclasts, as well as receptor activator of NFKB ligand (RANKL) [8] which is essential 
for chondroclast/osteoclast differentiation (reviewed in [5]). Estrogen regulates the closure of 
the epiphyseal growth plate and the skeleton maturation in human males as well as females, 
and estrogen receptor (ERα) expressed by the growth plate chondrocytes is a likely mediator 
of these effects [9-11].  
 
1.2  Composition of bone tissue 
The bone tissue consists of mineralized and non-mineralized matrix components as well as the 
bone cells. According to volume, the bone mineral hydroxyapatite (HAP) constitutes 
approximately 50% of the ECM, the rest being a mixture of collagen fibers, NCPs, 
proteoglycans, lipids and water where the exact composition varies dependent upon age, 
anatomic location, diet and general health status of the individual.  
 
1.2.1 Bone cells 
There are 3 different cells types in bone originated from 2 different cell lineages; 
mesenchymal cells give rise to the osteoblast lineage, which includes lining cells and 
osteocytes, in addition to adipocytes, myocytes and chondrocytes. The other cell line is the 
hematopoietic monocyte-macrophage lineage in the bone marrow which gives rise to the 
cartilage and bone macrophages known as chondroclasts/osteoclasts.  
The osteoblast is the bone forming cell, columnar in shape with a single, non-centric 
nucleus in its mature, active stage. Osteoblasts synthesize the bone matrix (osteoid) which 
comprises mostly collagen type I (COL1) as well as some minor collagens and proteoglycans, 
in addition to many of the NCPs such as integrin binding sialoprotein (IBSP), osteopontin 
(OPN), osteocalcin (OCN), osteonectin (ON) and the membrane-bound enzyme alkaline 
phosphatase (ALP), known to be an osteoblast marker. Osteoblasts originate from 
mesenchymal progenitor cells in the periosteum and bone marrow as well as in perivascularly. 
RUNX2 and Osterix (OSX) are two key transcription factors in osteoblast differentiation and 
facilitate the regulation of a variety of the different osteoblast-specific genes ([12]). RUNX2 
is one of the earliest markers of the osteoblast lineage and acts directly on the promoter for 
1 INTRODUCTION 
7 
 
OSX. Both Runx2 and Osx -/- mice completely lack osteoblasts demonstrating the essential 
role of these two transcription factors (reviewed in [13]). Numerous signaling pathways are 
involved in the differentiation, activation and inhibition of osteoblastic bone formation 
mediated through RUNX2 and OSX, among these are the BMPs, the WNTs, TGF-β, PTH, 
IGF-1, the FGFs and Notch (reviewed in [13-16]). In the end, 60-80% of the osteoblasts die 
by apoptosis. The remaining cells are either embedded in their own matrix during deposition 
of osteoid becoming osteocytes or they are converted into less active, flatten lining cells 
covering the bone surface.  
The osteocyte is the most abundant bone cell and is located in small lacunar areas in 
the mineralized matrix. It is stellate shaped with long cytoplasmic processes radiating from 
the cell body through small canals (canaliculi) in the mineralized matrix. These cytoplasmic 
processes connect the osteocytes to each other, the vessels in the Haversian canals, the bone 
surface with lining cells and osteoblasts as well as the cells in the bone marrow. During the 
transformation from mature, bone forming osteoblast to matrix embedded osteocyte several 
genes are switch on and off; one of the earliest osteocyte markers is E11/gp38/Podoplanin 
(PDPN), which seems to facilitate the formation of the dendritic processes/canaliculi. ALP is 
reduced, while casein kinase II and OCN is elevated in the late osteoblast and also expressed 
by the osteocyte. The mature osteocyte expresses markers such as phosphate-regulating gene 
with homologies to endopeptidases on the X chromosome (PHEX), matrix extracellular 
phosphoglycoprotein (MEPE), dentin matrix acidic phosphoprotein 1 (DMP1) and fibroblast 
growth factor 23 (FGF23) known to regulate phosphate metabolism. When the osteocyte 
senses the fluid-flow stress in the surrounding gel-matrix the cell responds by regulation of 
e.g. nitric oxide (NO), prostaglandin E2 (PGE2) and sclerostin. Sclerostin is a protein 
exclusively produced by osteocytes. It inhibits the canonical WNT/β-catenin signaling 
pathway reducing osteoblast differentiation from mesenchymal precursors and subsequent 
bone formation (reviewed in [17, 18]). Recently it has also been clarified that the osteocytes 
are the main source of RANKL in adult bone [19, 20] which is the main supporter of the 
osteoclastogenesis (reviewed in [14]) (Fig. 4). Osteocytes are also able to remodel their own 
environment (osteocytic osteolysis) under certain conditions, such as lactation, probably 
through the same mechanisms as the osteoclasts and in response to urgent need for bone 
mineral [21].  
The osteoclast is a multinucleated giant cell formed by fusion of mononuclear 
precursor cells of the monocyte-macrophage cell lineage derived from the circulation. The 
development of the osteoclastic phenotype is initially induced by the binding of colony 
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stimulating factor 1 (CSF1) to its receptor CSF1R which upregulates receptor activator of 
NFKB (RANK) on the cell surface (reviewed in [14]). 
 
 
Fig. 4 The RANK-RANKL-OPG axis The figure shows how membrane-bound RANKL in 
osteoblasts (Ob) and osteocytes (Ot) binds to RANK at the surface membrane of mononuclear 
precursor cells stimulating osteoclast (Oc) differentiation and activation [22, 23]. OPG may 
act as a decoy receptor for RANKL in addition to be an intracellular traffic regulator for 
RANKL to secretory lysosomes in both osteoblasts and osteocytes [23, 24]. 
 
RANKL, expressed by osteoblasts and osteocytes in addition to hypertrophic chondrocytes, is 
essential for further differentiation into bone resorbing osteoclasts and loss of function 
mutations in RANK or RANKL causes severe osteopetrosis (a high bone mass disease) due to 
impaired osteoclast function [25, 26]. It is not fully clarified whether membrane-bound 
RANKL or soluble RANKL activates RANK, however, it seems like membrane-bound 
RANKL is the most efficient osteoclast activator [22], (reviewed in [27]), and together with 
co-stimulation by the immunoreceptor tyrosin-based activation motif (ITAM)-containing 
adaptors, this leads to activation of the transcription factor NFATC1. NFATC1 is crucial for 
the osteoclastic phenotype and regulates the osteoclast specific genes (i.e. cathepsin K 
(CTSK), tartrate-resistant acid phosphatase (TRAP), matrix metalloproteinase 9 (MMP9) and 
β3-integrin) (reviewed in [14, 18, 28]). Osteoprotegerin (OPG), which is produced by 
osteoblasts and osteocytes in addition to B cells, endothelial cells and vascular smooth muscle 
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cells, serves as a decoy-receptor for RANKL and by binding to RANKL inhibits the 
activation of RANK (reviewed in [28, 29]) (Fig. 4). Continued stimulation through CSF1R 
and RANK is required for osteoclast survival and thereby making the RANK-RANKL-OPG 
axis a suitable target for therapeutic agents aiming at diminishing bone resorption.  
Prior to bone resorption, the maturing osteoclast must attach to the targeted 
mineralized matrix before the final differentiation occurs. The binding of osteoclastic 
vitronectin receptor (Įvȕ3-integrin) to e.g. OPN enriched at the bone surface [30, 31], seems to 
facilitate the further polarization and reorganization of the actin cytoskeleton forming an F-
actin ring “sealing” the osteoclast to the surface (sealing zone, SZ). This isolates a membrane 
area that develops into the ruffled border (RB) (reviewed in [14, 32]). Simultaneously, a 
functional secretory domain (FSD) develops at the basolateral side allowing the phagocytosed 
bone constituents to be secreted into the circulation [33]. The SZ and the RB form a closed 
space, the osteoclast resorption pit, where acidification of the environment promotes bone 
resorption (Fig. 5). What stops the osteoclastic bone resorption is not fully clear, but after a 
few weeks the osteoclast undergoes apoptosis. Estrogen via TGF-β as well as soluble Fas 
ligand (FASLG) from the osteoblasts acting on the Fas receptor (FAS) in the osteoclasts 
membrane are known to decrease bone resorption by inducing osteoclast apoptosis. These 
mechanisms are further detailed in 1.3. 
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Fig. 5 The bone resorbing osteoclast (Oc) attaches to bone via Įvȕ3-OPN binding creating a 
sealing zone (SZ). An isolated membrane area develops into the ruffled border (RB) exposing 
a large surface area towards the bone. Bone resorption occurs at low pH promoting 
dissolution of bone mineral and degradation of collagen type I by acidic proteases such as 
cathepsin K and the MMPs. Collagen remnants, calcium (Ca2+) and phosphate (PO43-) as well 
as other molecules are endocytosed and secreted into the circulation via the functional 
secretory domain (FSD). TRAP may serve as a detachment-factor promoting osteoclast 
migration by dephosphorylation of e.g. OPN [34] as well as collaborate in the degradation of 
bone remnants in transcytotic vesicles (Tv) together with cathepsin K [35]. 
 
1.2.2 Extracellular bone matrix 
In all bone types the ECM consist of collagen fibrils, NCPs, small amounts of phospholipids, 
serum proteins and water in addition to HAP. In compact bone collagen type I comprises over 
90% of the organic matrix while the rest of the bone proteins being NCPs, however the ratio 
differs between the various bone types, with woven bone (newly formed bone) being the one 
with the highest NCPs content (reviewed in [36]).  
Collagens make up the structural framework in bone and other connective tissues and 
represent a large family of proteins, accounting for nearly 30% of all human proteins. In bone, 
the collagens fibrils contribute to its fracture resistance and elastic properties, as well as 
playing an important role as a structural template for mineral deposition. Collagen type I is 
predominant in bone, while collagen type II is the main constituent in hyaline cartilage. Other 
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collagens are present as well, however in small amounts. Collagen I and II are rod-like 
structures derived from the aggregation of 3 polypeptide chains (in collagen type 1: 2 α1(I) 
chains and 1 α2(1) chain) fold into a triple helix molecule, where the polypeptide chains are 
characterized by a triplet repeat sequence (gly-x-y, where gly is glycin, x usually is proline 
and y often hydroxyproline). The collagen molecules assemble into fibrils stabilized by cross-
links within and in-between the collagen fibrils. These bone-derived collagen cross-links 
(CTX) can be measured in the urine to monitor bone resorption.  
Non-collagenous matrix proteins are a heterogeneous group of different proteins 
participating and controlling bone mineralization as well as being involved in bone and 
energy metabolism (e.g. OCN). Most NCPs are acidic proteins containing glutamic acid, 
aspartic acid, and phosphorylated serine/threonine residues. In addition, many of them have a 
high capacity for binding calcium ions and to HAP crystal surfaces [37].  The NCPs can be 
divided into subgroups according to their main components as proteoglycans, glycoproteins or 
Ȗ-carboxylated (gla) proteins. Most of the NCPs are produced locally by the cells of the 
osteoblastic lineage, but approximately one-fourth are produced elsewhere, mainly in the 
liver. These exogenously derived proteins are transported in the circulation and suggested to 
bind to bone matrix because of their high affinity to HAP. Many are acidic serum proteins 
(such as albumin and Į2-HS-glycoprotein) which may be of importance in bone 
mineralization or play a role in circulating calcium transport. The NCPs are suggested a role 
as biological modulators rather than exhibiting structural support. Their regulatory function of 
mineralization as well as crystal growth within osteoid is supported by knock-out/transgenic 
experimental studies reporting dramatic phenotypic abnormalities in the mineralization 
process (the function of each protein is reviewed in [36, 38]). However, their concerted role in 
the mineralization of bone is still elusive.  
 
1.2.3 Matrix mineralization 
Bone mineral is essential for the mechanical properties and integrity of the bone tissue and 
serves as the most important ion reservoir of the body. Bone mineral is present mainly as a 
complex of calcium and phosphate, quite close to naturally occurring geologic 
hydroxyapatite, [Ca10(PO4)6OH2], but the crystals are smaller, less perfect and contain several 
impurities. The imperfect composition of the HAP crystals provides increased solubility and 
eases the release of ions into the circulation. However, as the bone matures the crystals 
increase in size and become more perfect. The HAP crystals are deposited between the 
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collagen fibrils and there are two essential events in the mineralization process of bone; the 
first is the nucleation of the crystals with a length axis, the other is the crystal growth. Matrix 
vesicles, mineralization foci, “crystal ghosts”, calcospherulites, phosphoproteins-collagen 
fibrils and Į2-HS-glycoprotein have been suggested candidates responsible for the initiation 
and controlling of the mineralization process, thus it is likely that they all, to some extent, 
play a role (reviewed in [38]). After the initial mineral deposition into the “holes” between the 
collagen fibrils, the crystals enlarge and mature by the aggregation of new ions enabling 
growth to occur in more than one direction in an exponential fashion. The NCPs act probably 
as controllers and may bind to and thus regulate the size and shape of the crystals [39]. In 
addition, several other substances are known to affect the growth and maturation of HAP in 
bone. For example, dietary cations (Mg2+, Sr2+), the toxic pollutant cadmium (Cd2+), as well 
as carbonate (CO3-) and citrate in the body fluids may incorporate or substitute other ion 
groups leading to smaller, less perfect and thus more soluble crystals. The opposite effect is 
caused by incorporation of fluoride (F1-) which increases the crystal size thus decreases the 
solubility. Bisphosphonates, which are extensively used in the treatment of osteoporosis, 
incorporates in bone during the HAP crystal formation due to their high affinity for calcium. 
When bone resorption occurs, the bisphosphonates are released inhibiting osteoclast function 
and stimulating apoptosis and thereby further bone resorption. In addition, tetracycline binds 
with high affinity to the surface of recently formed HAP crystals and may be used to 
determine bone turnover [40].  
 
1.3  Bone remodeling 
Bone models and remodels continuous throughout life in a tightly coupled process of bone 
resorption and formation carried out by the osteoclasts and the osteoblasts. Bone modeling 
occurs during growth when the skeleton shapes and changes to achieve its structure and 
function. Remodeling is the continuous replacement of old bone (or cartilage) with new bone. 
The purpose of bone remodeling is not well known, however, removing dead osteocytes and 
microcracks as well as to maintain oxygen and nutrient supply to keep a healthy skeleton are 
likely reasons. Bone remodeling may also occur in response to hormonal regulation e.g. to 
release calcium and phosphate to the blood. Bone is remodeled in small units called the bone 
multicellular unit (BMU) which consists of a bone resorbing osteoclasts in front followed by 
bone forming osteoblasts (Fig. 6). When remodeling occurs in cortical bone the BMU (also 
called an osteon) excavates and replaces a canal (Haversian canal) axial to the applied 
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mechanical force. In cancellous bone, remodeling occurs across the trabeculaes excavating 
and replacing small packets of bone. At any moment more than a million BMUs are operating 
in the skeleton of healthy adults renewing the whole skeleton every 10 year.  
 
 
Fig. 6 Bone multicellular unit (BMU) with a leading bone resorbing osteoclast (Oc) in front 
followed by a team of bone forming osteoblasts (Ob). A central capillary and a nerve (in the 
top of the figure) are also present in the BMU.  
 
The bone remodeling cycle consists of 3 phases: The resorption phase where the 
osteoclasts remove bone; the reversal phase with the formation of the “cement line”, a 
glycoprotein-rich material laid down by what seems to be premature osteoblastic cells that 
gradually differentiates into bone forming osteoblasts [41]; and the formation phase where the 
mature osteoblasts form new bone. These phases occur with different speeds: resorption 
continues for about 14 days, reversal for 4 to 5 weeks while bone formation may take several 
months before a new structural unit is fully formed (reviewed in [18]). This means that if bone 
resorption is accelerated, a temporary imbalance occurs between resorption and formation. 
During the last decade it has been clarified that the osteocyte is a main orchestrator of bone 
remodeling by regulating both the resorption and the formation. Recent studies have 
demonstrated that the osteocyte is the main source of RANKL [19, 20] in adult bone. In 
1 INTRODUCTION 
14 
 
addition, the hypertrophic chondrocyte also express RANKL [8, 20]. This may indicate that 
the bone resorption process is more targeted than stochastic as the cells in or near areas in 
need for bone resorption are the ones initiating it. In adult bone the apoptotic osteocytes or 
their surviving neighbors have been suggested to determine the targeted sites for the bone 
resorption (reviewed in [18]). However, the remodeling sequence is regulated by several local 
as well as systemic factors (Table 1) and many are mediated through the RANK-RANKL-
OPG axis (Fig. 4). 
 
1.3.1 Regulation by local factors 
It is well known that increases or decreases in the rate of bone resorption are tightly followed 
by the same response in the rate of bone formation. Over the years much attention has been 
paid to the “coupling” between resorption and formation, trying to identify a main “coupling-
factor”. The osteoclastic bone resorption releases a lot of growth factors from the mineralized 
matrix which stimulate osteoblast differentiation, proliferation and activation. TGF-β, IGF-
I/II and the BMPs are among these. Osteoclasts may also regulate osteoblasts directly through 
e.g. binding of the transmembrane protein ephrin-B2 (EFNB2) to its receptor EPHB4 on 
osteoblasts leading to decreased osteoclast activity and increased osteoblast differentiation 
[42]. In addition, osteoclasts may secrete osteoblast stimulatory factors such as WNT10b and 
BMP6 (reviewed in [43]). Moreover, the osteocyte expresses sclerostin, the product of the 
SOST gene. Sclerostin inhibits bone formation via the canonical WNT/β-catenin pathway by 
binding to LRP5/6 which further inhibits the binding of WNTs with subsequent degradation 
of β-catenin in cytosol and shutdown of the differentiation from mesenchymal precursors into 
bone forming osteoblasts. By suppressing sclerostin (by e.g. mechanical loading or PTH) the 
canonical WNT/β-catenin pathway is activated and β-catenin accumulated in the nucleus 
stimulates osteoblast differentiation. In mature osteoblasts and osteocytes β-catenin 
upregulates OPG, inhibits RANKL and thereby decreases osteoclastogenesis and bone 
resorption. Targeted deletions in the sclerostin gene in mice (Sost) cause high bone mass and 
increased bone strength as does the rare disorder sclerostosis among humans (reviewed in [14, 
17]). Sclerostin antibodies have shown promising results as bone anabolic therapeutics in 
osteoporosis as well as to improve fracture healing [44].  
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1.3.2 Regulation by systemic factors 
Parathyroid hormone (PTH), 1,25(OH)2 vitamin D3 (1,25D), calcitonin, and estrogen are 
pivotal in bone remodeling, however, also other hormones including growth hormone (GH), 
thyroid hormone and glucocorticoids contribute to the regulation. A predominant function of 
PTH, 1,25D and calcitonin is to maintain adequate calcium and phosphate levels in the 
circulation using bone as a mineral reservoir.  
PTH is secreted from the parathyroid glands and targets the kidneys as well as bone. 
Low levels of calcium and high levels of phosphate in the circulation stimulate PTH secretion 
which leads to enhanced renal tubular reabsorption of calcium and increased excretion of 
phosphate and bicarbonate. In addition, vitamin D is hydroxylated in the kidneys under 
influence of PTH to achieve its active form 1,25D. In bone PTH stimulates bone resorption 
via its receptors on osteoblasts and bone marrow stromal cells increasing CSF1 and RANKL 
and decreasing OPG (reviewed in [14]), however, data have also been reported on possible 
PTH receptors in osteoclasts [45]. Dependent upon mode of administration exogenous PTH 
has dual effects on bone remodeling; continuous PTH administration leads to increased bone 
resorption, while intermittent administration leads to increased bone formation. The latter may 
in part be due to the reduced levels of sclerostin by PTH (reviewed in [17]).  
Vitamin D belongs to a group of sterols where vitamin D2 and D3 are the most 
important. It is crucial for calcium and phosphate absorption from the intestine and adequate 
levels of these ions have to be present to permit proper bone mineralization. Vitamin D2 is 
plant-derived while vitamin D3 is synthesized in the skin from cholesterol in response to UVB 
radiation, however both can be introduced through the diet. To achieve its active form, 1,25D, 
vitamin D needs to be hydroxylated in the liver (to calcidiol, 25D) and subsequently in the 
kidneys (to calcitriol, 1,25D) under stimulation of PTH for optimal function in target tissues. 
1,25D acts in a negative feedback loop on PTH synthesis in the parathyroid glands as well as 
induces FGF23 synthesis in the osteocytes which in turn downregulates the synthesis of 
1,25D in the kidney. These loops maintain a steady level of calcium and phosphate in the 
circulation preventing hypo- as well as hyperstates [46]. 1,25D mediates its effects via the 
vitamin D receptor-retinoid X receptor (VDR-RXR) complex acting directly on vitamin D 
responsive elements (VDRE) in the DNA of 1,25D regulated genes. In bone cells the VDR is 
present in osteoblasts, osteocytes and growth plate chondrocytes where the activation 
stimulates the expression of e.g. OCN, OPN, LRP5, and FGF23 [46-48]. At high non-
physiological concentrations and under conditions with low levels of circulating calcium and 
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phosphate, 1,25D stimulates RANKL mediated bone resorption to mobilize ions to the 
circulation and represses the expression of OPG and RUNX2 [46, 47].  
Calcitonin is a peptide hormone produced by the interstitial C-cells in the thyroid 
gland and the synthesis is stimulated by increased levels of serum calcium. Although 
influencing calcium homeostasis, calcitonin is less important than PTH and 1,25D and has the 
opposite effect by lowering the serum calcium. It inhibits osteoclastic bone resorption, 
however only transiently because the osteoclasts escape from the inhibitory effect after 
prolonged exposure probably due to down regulation of receptor mRNA [49].   
Estrogen is the most important bone-sparing hormone in the skeleton for both sexes 
(reviewed in [43, 50]). The crucial effects of estrogen on bone tissue are illustrated by the 
phase of accelerated net bone loss following menopause; ovarian failure and declining 
estrogen levels increases bone resorption which outstrips the fine-tuned coupling to bone 
formation. The effects of estrogen is mainly mediated through intranuclear receptors (ERs), 
which are expressed in osteoblasts [51], osteocytes [52], osteoclasts [51-53] as well as in T-
cells [54]. Two types of ERs, ERĮ and ERȕ [55] are present in bone. It is considered that the 
bone-conserving effects of estrogen are modulated via osteocytes, which seems to be the main 
controller of bone remodeling. Estrogen promotes survival of osteocytes by inducing a 
cascade leading to inactivation of the pro-apoptotic protein BCL2-assosiated death promoter 
(BAD) (reviewed in [43]), while estrogen withdrawal increases osteocyte apoptosis and 
thereby trigger bone remodeling [56]. Estrogen also acts directly upon osteoclastic bone 
resorption by inhibiting activation of genes encoding important factors for osteoclasts 
development, such as IL6, TNF-Į and CSF1 as well as suppressing TNF-Į gene expression 
leading to decreased osteoclast number and activity [57]. Estrogen blocks the effects of 
RANKL and CSF1 in osteoclasts, decreases the production of RANKL by osteoblasts and T 
and B cells and upregulates the synthesis of OPG (reviewed in [43]) in addition to TGF-β by 
osteoblasts inducing osteoclast apoptosis. A recent study [58] has shown that estrogen 
upregulates MMP3 cleavage of FASLG in the osteoblasts membrane. This leads to increased 
levels of soluble FASLG inducing apoptosis via FAS in osteoclast precursors as well as in 
mature osteoclasts and thereby inhibiting bone resorption. Estrogen also favors net bone 
formation by binding to its ER receptor in osteoblasts reducing oxidative stress and apoptosis. 
In sum these results offer an explanation to why estrogen withdrawal is so devastating for 
bone mass; the increased number of bone remodeling sites due to enhanced osteocyte 
apoptosis and bone resorbing osteoclasts in addition to increased osteoblast apoptosis with 
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reduced bone formation, explain why estrogen deficiency leads to a gap between resorption 
and formation with a resulting net bone loss.  
 
Table 1 Overview of some local and systemic factors acting upon bone remodeling 
Factor Bone resorption Bone formation 
BMPs - ↑ differentiation of Ob via RUNX2 
TGF-β ↓ → ↑OPG and ↓RANKL ↑ differentiation of Ob 
Sclerostin ↑ → ↓OPG and ↑RANKL ↓ differentiation of Ob via ↓β-catenin 
NO - ↑ bone formation 
PGE2 - ↑ bone formation 
Insulin ↑ → ↓OPG and ↑RANKL - 
Leptin ↓ → ↑CART → ↓RANKL 
↑ → ↑SNS →↑RANKL 
 
↓ Ob proliferation via ↑SNS 
1,25D ↑ → ↓OPG and ↑RANKL ↑ bone formation and mineralization via 
LRP5, OPN, OCN 
↓ Ob differentiation via RUNX2 
PTH ↑ → ↓OPG and ↑RANKL (↑) intermittent → ↓ sclerostin levels 
Calcitonin ↓  inhibits Oc differentiation - 
Glucocorticoids ↑ Oc survival ↓ by suppression of Ob differentiation and 
stimulation of Ob and Ot apoptosis 
Estrogen ↓ Increases Fas induced Oc 
apoptosis directly and via Ob 
↓ Blocks RANKL/CSF1  
↓→ ↑OPG and ↓RANKL by Ob, T 
and B cells 
↑ bone sparing effect due to pro-survival 
signaling in Ot  
↑ by inhibiting oxidative stress and Ob 
apoptosis 
↑ by inhibiting sclerostin? 
 
 
1.4 Bone as an endocrine organ 
Recent data suggest that bone may function as an endocrine organ. Osteoblasts, in addition to 
its well known synthesis of collagen type I and bone matrix proteins also produce the 
hormone osteocalcin (OCN) which is carboxylated by vitamin K and stored in mineralized 
bone matrix. OCN is suggested to play a role in an endocrine axis where bone participates in 
the regulation of energy metabolism. When bone resorption occurs, OCN is 
undercarboxylated and activated by the acidic environment in the osteoclast resorption pit and 
secreted into the circulation where it stimulate the β-cells to increase insulin synthesis in the 
pancreas, the testosterone synthesis in male gonads, as wells as increases insulin sensitivity in 
muscles, adipose tissue and liver. A positive feedback loop occurs when insulin inhibits OPG 
in osteoblasts, up-regulates RANKL secretion and thereby bone resorption allowing more 
OCN to be activated and secreted into the circulation (reviewed in [14, 59]). On the other 
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hand, leptin, a hormone produced by adipose tissue, also controls the bioactivity of OCN via 
actions involving the sympathetic nervous system (SNS) favoring decarboxylation of OCN 
and thereby decreases OCN activity. In addition, leptin acts on bone metabolism via two 
different pathways with opposite effects that in sum prevent bone mass accumulation; it 
inhibits osteoblast proliferation and stimulates RANKL and bone resorption via SNS as well 
as decreases RANKL expression via cocaine- and amphetamine-regulated transcript (CART) 
(reviewed in [59]).  
Another endocrine factor produced in bone is fibroblast growth factor 23 (FGF23). 
FGF23 is synthesized in the osteocyte under stimulation of VDR-RXR by 1,25D and targets 
the kidneys where it binds to FGFR-α-Klotho complexes in kidney tubules and stimulates the 
elimination of phosphate as well as feedback represses the synthesis of 1,25D in the kidney. 
FGF23 synthesis is also enhanced by high circulating phosphate levels and decreased by 
PHEX and DMP1, two other osteocyte derived factors, allowing reabsorption of phosphate in 
the kidneys to maintain sufficient phosphate levels and subsequent mineralization of bone. 
High circulating FGF23 levels are associated with hypophosphatemic rickets and 
osteomalacia. Low levels are associated with hyperphosphatemia, increased 1,25D and 
ectopic calcification (reviewed in [17, 60, 61]). Interestingly, lower expression of FGF23 was 
observed in the fracture callus of our rats with experimental osteoporosis compared to normal 
controls [62].  
 
1.5  Bone biomechanics and fracture repair 
Knowledge of bone construction is essential to understand bone biomechanics. A compact 
cylinder is extremely strong but heavy, thus the intelligent construction of the skeleton can be 
illustrated by the long bones; they are thick-walled pipes possessing mechanical strength but 
still relatively light due to their tube form. Bone area reflects bone mineral density (BMD), 
but the second moment of area (m4) is a property of shape that is used to predict resistance of 
materials to bending and deflection. In brief, assumed the same bone area, a tubular structure 
has greater resistance to bending than a massive cylinder due to efficient distribution of 
material. Increasing the diameter and decreasing the cortical wall thickness of a tube increases 
the second moment of area, thus increasing the resistance to bending. This can be illustrated 
by appositional bone growth; bone added periosteally increases the bending strength of the 
bone more than the increase in bone area, even if the absolute bone volume and BMD are 
unchanged (reviewed in [63]). 
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1.5.1 Biomechanical properties of bone 
Materials can be described as weak or strong, ductile or brittle, stiff or compliant dependent of 
the outcome of a stress-strain test (e.g., the load-deflection curve obtained by loading a bone 
specimen until failure, Fig. 7). Stress is the load per unit area. Strain (deflection) is the 
percentage change in length calculated as the size of deformation divided on the original 
length of the specimen. The slope of the linear region of the stress-strain curve is called the 
Young’s modulus of the material, representing stiffness; the greater the slope, the stiffer the 
material. The height of the curve represents the ultimate moment (stress), which is a measure 
of strength. The yield point is the point where the curve begins to bend. Prior to the yield 
point the bone bends elastically and will return to its original shape when the applied stress is 
removed. Once the yield point is passed some fraction of deformity will be permanent. The 
area under the curve (the integral of the function f(x)) is the amount of energy the tissue can 
resist before failure (energy absorption) and is also called toughness. Thus, a bone that is 
strong and stiff may require less energy to fracture (less area under the load-deflection curve) 
than a weak, compliant bone.  
The components of bone have different impact on the mechanical properties; the 
intermolecular cross-links in collagen are suggested to enhance bone toughness [64, 65], 
while the fiber orientation is considered critically important to bone strength. The latter is 
supported by the fact that collagen fibers tend to be orientated axial to the applied external 
force [66, 67]. This can be illustrated by the congenital pathologic condition osteogenesis 
imperfecta, “the brittle bone disease”, caused by different mutations in the genes encoding 
collagen type I making the affected individuals prone to low trauma-fractures. Bone mineral 
provides strength and stiffness, and the mineral to collagen-ratio affects both parameters. As 
the fraction of the mineral volume increases, Young’s modulus is improved (increased 
stiffness), but ultimate strain (deflection) decreases and the bone becomes more brittle. The 
adult variant of vitamin D deficiency, osteomalacia, with failure of normal bone 
mineralization makes the bones more prone to deformation during loading “soft bones”, thus 
fractures do not easily occur due to the decrease in mineral volume fraction.   
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Fig. 7 Three-point cantilever bending test Load-displacement curve from mechanical 
testing of a rat femur demonstrating the ultimate moment/bone strength (top of the blue 
curve), bending stiffness (the slope of the linear region, red line), deflection (the ultimate 
deformation of the bone before fracture) and energy absorption/bone toughness (the 
integrated f(x)). 
 
1.5.2 Fracture repair 
A bone fracture can be defined as a discontinuity in the bone tissue as a result of mechanical 
injury or insufficient strength of the bone tissue itself [68]. When fracture occurs, the body 
responds by general wound healing processes as well as tissue specific bone repair with 
almost complete restoration of the original anatomy. Fracture healing includes both 
intramembranous and endochondral bone formation. Direct intramembranous bone formation 
(primary ossification) is rare and permits direct reestablishment of cortical bone by the 
cortical components themselves and is most likely to occur if anatomic reduction and stabile 
fixation has been carried out. However, there is usually some flexibility in the stabilized 
fracture which promotes healing via the formation of a cartilagenous template and several 
steps from the endochondral bone formation are recapitulated.  
1 INTRODUCTION 
21 
 
The fracture healing process is often divided into 4 phases: The inflammatory phase is the 
initial body response to tissue damage and is much the same as in general wound repair. A 
fracture hematoma is formed due to vascular damage. Platelets are activated and 
inflammatory cells infiltrate the hematoma which subsequently reorganizes into granulation 
tissue with newly formed vessels and fibroblasts laying down collagen. The hematoma with 
platelets and inflammatory cells is an important source of osteogenic signaling molecules 
resulting in recruitment of osteoprogenitor cells from the periosteum, bone marrow and the 
surrounding soft tissue. Multiple growth factors and cytokins coordinate the process e.g. 
macrophage derived growth factor (MDGF), platelet derived growth factor (PDGF) and 
fibroblast growth factors (FGFs) as well as members of the TGF-β superfamily, interleukins 
and BMPs are involved (reviewed in [69]). The central role of the inflammatory phase can be 
illustrated by the effect of anti-inflammatory agents, such as non-steroidal anti-inflammatory 
drugs (NSAIDs), resulting in increased fibrinogenesis, decreased bone formation and delayed 
fracture healing (reviewed in [70]). The formation of soft callus is the start of the reparative 
phases which is dominated by the formation of a cartilaginous callus promoting early 
stabilization to the fracture site and serving as a template for the later bony callus formation. 
This is much a repetition of the endochondral bone formation process with mesenchymal 
precursor cells differentiating into chondrocytes and hypertrophic chondrocytes with cartilage 
maturation and mineralization [71] (see 1.1.1 for details). The formation of hard callus 
describes the osteogenesis which also occurs during direct, primary ossification if the fracture 
stabilization is sufficiently rigid. As soon as the cartilage is mineralized the in-growth of 
vessels allows the osteoprogenitors to proliferate and differentiate into bone-forming 
osteoblasts synthesizing new, irregular bone (woven bone). The hypertrophic chondrocytes 
stimulate differentiation of chondroclasts/osteoclasts by increasing levels of CSF1 and 
RANKL promoting resorption of the mineralized cartilage, while members of the BMP family 
promote recruitment of the osteoprogenitors and VEGF stimulates neoangiogenesis (reviewed 
in [69, 72]). The remodeling phase begins when the cartilage is resorbed and the callus almost 
exclusively consists of woven bone (after approximately 3-6 weeks). The final remodeling of 
the callus from woven bone into the original cortical or trabecular configuration with the re-
establishment of the marrow cavity, may take months or even years and is driven by a coupled 
process of osteoclastic bone resorption and osteoblastic bone formation similar to regular 
bone remodeling.  
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1.6  Osteoporosis 
Osteoporosis (greek; ostoun meaning bone and poros meaning pore) is an age-related bone 
disorder affecting both men and women where imbalance between bone resorption and 
formation leads to a net bone loss with resulting bone fragility and increased fracture risk. 
BMD is reduced as a measure of bone loss and the bone microarchitecture is deteriorated. 
Osteoporosis is the most frequent bone disorder in the world and the most common metabolic 
disorder among the elderly (reviewed in [73]). The condition is a major health problem not 
only for the affected individuals but also for the society. In Norway the costs of hip fractures 
alone has been estimated to 2.0 billion NOK a year [74]. Norway and Sweden as well as 
northern parts of the United States have the highest prevalence of osteoporosis worldwide 
[75], and although the incidence of hip fractures in Norway has decreased over the last decade 
it is still the highest in the world [76]. As the populations in the western world are getting 
older fragility fractures are expected to increase although the age-related incidence is 
unchanged or decreasing. The World Health Organization (WHO) has defined osteoporosis in 
both men and women as BMD values 2.5 standard deviations or more below the BMD for the 
young, healthy female Caucasian measured by dual-energy X-ray absorbtiometry 
(DEXA/DXA) [77]. Established osteoporosis includes, in addition to low BMD, the presence 
of a fragility fracture and the hip, distal forearm, spine and proximal humerus are especially 
prone to such fractures. However, BMD alone is not sufficient to predict the risk of a future 
fragility fracture, and the WHO therefore recommend the use of FRAX 
(www.shef.ac.uk/FRAX/tool.jsp) which is the WHOs fracture risk assessment tool. This tool 
incorporates several known risk factors for osteoporosis and fractures including BMD, and 
predicts the patient’s 10 year probability of fracture. The set up also contains 
recommendations for anti-osteoporotic therapy.  
New perspectives on osteoporosis as a part of the frailty syndrome classify osteoporosis 
as a degenerative disorder in line with atherosclerosis, myocardial hypertrophy, insulin 
resistance and Alzheimer’s disease. This has lead to a focus shift from the “estrogenocentric” 
view highlighting postmenopausal estrogen deficiency towards increases in cellular oxidative 
stress being the main pathological mechanism causing osteoporosis (reviewed in [73]). 
However, it is well documented that an accelerated rate of bone loss is taking place right after 
menopause [78] due to the withdrawal of estrogen and the hormone’s bone-sparing “anti-
oxidative” effects.  
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Bone loss begins in the thirties for both men and women. After reaching the peak bone 
mass in the early thirties, the continuous remodeling of the skeleton slowly looses bone as the 
defense against oxidative stress in the organism is reduced. Consequently, individuals with 
low peak bone mass are more prone to osteoporosis and fragility fractures. Low peak bone 
mass is influenced by several genetic and non-genetic factors; among the genetic determinants 
are female sex, body mass index (BMI) and age at menarche [79] in addition to 
polymorphisms in genes regulating bone mass e.g., VDR [80], COLIA1 [81], the genes 
influencing the WNT/β-catenin pathway such as the LRP5, DKK and SOST [44, 82, 83] as 
well as some more un-known genes associated with BMD [83]. The non-genetic factors 
contributing to low peak bone mass are e.g. low daily calcium intake during childhood, low 
body weight, sedentary lifestyle and delayed puberty [84, 85] as well as some therapeutics 
e.g. glucocorticoids and anti-convulsives. 
 
1.7  Vitamin D deficiency 
Vitamin D deficiency may be due to inadequate intake or absorption from the intestine, 
defects in the synthesis, or vitamin D resistance in the target tissues (reviewed in [86]). 
Vitamin D inadequacy is common among the elderly [87, 88] leading to decreased intestinal 
calcium absorption and increased levels of PTH (secondary hyperparathyroidism). This 
results in enhanced bone turnover as well as fatigue and muscle wakening increasing the risk 
for falls. Severe vitamin D-deficiency during childhood or in the adults manifests in bone as 
either rickets or osteomalacia, respectively, due to the insufficient mineralization of osteoid 
and/or the periosteal/endosteal appositional growth. In children, rickets includes failure of 
and/or delayed mineralization of growth cartilage at the epiphyseal growth plate which 
becomes thick, wide and irregular. Clinically rickets/osteomalacia manifest with skeletal 
deformities, bone pain and pseudofractures (reviewed in [89]).  
 
1.8 Tartrate-resistant acid phosphatase 
Tartrate-resistant acid phosphatase (TRAP) (ACP5), also known as purple acid phosphatase, 
or uteroferrin [90], is a well known enzyme demonstrated in many mammalian tissues [91-
93], and most known as an osteoclast marker. Acid phosphatase activity in bone was 
described as early as in 1969 [94] and in 1977 it was confirmed that there are 2 types of acid 
phosphatases (ACPases) in bone tissue; tartrate-sensitive ACPase and tartrate-resistant 
ACPase [95]. TRAP belongs to the subfamily of purple acid phosphateses (PAP), a group of 
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metalloenzymes [96] which catalyzes hydrolysis of phosphate esters and anhydrides under 
acidic conditions. Mammalian TRAP enzymes are glycoproteins with a molecular weight of 
approximately 35 kDa. TRAP is synthesized as a relatively inactive pro-enzyme (monomeric 
TRAP/mTRAP/loop-TRAP/serum TRAP 5a) and proteolytic cleavage by members of the 
cathepsin family or other proteinases, increases the catalytic activity at least 10-fold [97, 98].  
TRAP gene expression seems to be most abundant in bone tissue [99] where it has shown 
several biological abilities; e.g., dephosphorylation of OPN and IBSP [100, 101], and of Man-
6-P recognition marker on lysosomal proteins [102, 103] as well as generation of reactive 
oxygen species (ROS) [35] for bone matrix degradation. Human serum contains two isoforms 
of TRAP; 5a and 5b with different pH optimum; 5.0-5.2 and 5.8-6.0 respectively. Serum 
TRAP 5a is identical to monomeric TRAP, while serum TRAP 5b is identical to osteoclastic, 
cleaved TRAP (reviewed in [104]). The serum activity of TRAP 5b is significantly elevated in 
patients with osteoporosis and negatively correlated with BMD [105]. Studies on mice have 
yielded similar results: overexpression of TRAP results in enhanced bone turnover and a mild 
osteoporotic phenotype [106], while global deletion of TRAP leads to disturbed endochondral 
ossification with widening of the growth plate as well as an enhanced number of thickened 
trabeculae in the metaphysis and a mild osteopetrotic phenotype [107-109]. 
TRAP has also been reported in osteoblasts and osteocytes [94, 110-117]; TRAP 
mRNA and enzyme activity have been demonstrated in the metaphysis and in the endosteal 
and periosteal aspects of diaphyseal rat bone [110, 116] as well as in osteocytes in diaphyseal 
rat bone near bone resorption sites [110, 113]. The origin and function of TRAP in these cells 
have been debated; one hypothesis is that osteoclastic TRAP from the resorption lacunae is 
endocytosed by osteoblasts. This theory is supported by cell culture studies reporting that 
osteoblast-like cells are able to engulf osteoclastic TRAP and inactivate the enzyme, 
suggesting that this could control the enzyme activity and prevent further degradation of 
matrix constituents [114, 115].  However, endogenous TRAP production has also been 
demonstrated in osteoblasts [116] and osteocytes [113] in areas close to bone resorbing 
surfaces suggesting that TRAP may take part in mechanisms controlling the direction of 
osteoclastic bone resorption [113]. There are also in vitro results indicating that TRAP in the 
osteoclast lacunae may play a role in the signaling pathway responsible for the differentiation 
of osteoblast-like cells into mature osteoblasts and thereby being one of the “coupling-
factors” between bone resorption and bone formation [118]. In addition, increased amounts of 
TRAP and cathepsin K have been demonstrated in large osteocyte lacunae and canaliculi in 
lactating mice, suggesting that osteocytes are able to remodel their matrix via osteoclast-like 
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mechanisms under specific conditions [21]. Despite excessive studies on TRAP in bone, the 
exact function(s) still remains elusive. 
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2 AIMS OF THE STUDIES 
 
In the current project the initial goal was to establish an animal model for studies of fracture 
healing in osteoporosis as well as to use animal models with disturbed bone turnover to 
provide new insight into bone metabolism at the molecular level.  
 
Paper I 
In the first paper we aimed to establish the experimental osteoporosis model by the 
combination of ovariectomy and vitamin D deficiency in rats, and use this model to test the 
hypothesis that experimental osteoporosis delays bone repair manifested as impaired 
mechanical properties and bone mineral density of the fracture callus. 
 
Paper II & III 
In paper II we wanted to test the hypothesis that tartrate-resistant acid phosphatase (TRAP) in 
osteoblasts and/or osteocytes in rat bone tissue mainly has an exogenous osteoclastic origin in 
vivo by demonstrating enhanced levels of TRAP in such cells in animal models with increased 
osteoclast activity; i.e. in experimental osteoporosis and in experimental rickets. The second 
hypothesis was that endocytosed TRAP in osteoblasts and/or osteocytes will locate to late 
endosomes or lysosomal structures for subsequent inactivation and degradation or further 
signaling (cf. Fig. 8). 
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Fig. 8 The endocytosis theory for TRAP in osteoblasts A schematic drawing of the 
suggested routes for osteoclastic TRAP (TRAP-Oc) which is endocytosed by osteoblasts for 
either lysosomal degradation or for serving as a coupling factor promoting Ob maturation. 
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3 MATERIALS AND METHODS 
 
An overview of the animal models and the methods applied in the included papers are given 
below. The reader is referred to the respective papers for further details.  
 
3.1 Animal models and study designs 
Local guidelines as well as the American Guide for the Care and Use of Laboratory Animals 
[119, 120] were followed and the protocols approved by the Norwegian National Animal 
Research Authority for the animal experiments included in this thesis. The numbers of 
animals were kept to a minimum in accordance to the statistical power analyses. The surgical 
procedures (ovariectomy and induction of a standardized fracture) were carried out under 
deep anesthesia and all animals received subcutaneous analgesics after the procedures and the 
first postoperative day. Blood samples were collected from the animals in paper I and II prior 
to killing. During the in vivo experiments all the animals were housed under standard 
laboratory conditions (except for the rats with experimental rickets which were kept in a room 
with UV-free light) in a well equipped animal laboratory (Department of Comparative 
Medicine, Oslo University Hospital, Rikshospitalet). The animals were taken daily care of by 
professionals as well as the researchers during the experiments. The animals gained weight 
during the course of the in vivo experiments and killing of all animals was performed either 
under deep anesthesia and in vivo perfusion through the hearth, by a phenobarbital overdose 
or by a guillotine.  
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Fig. 9 Schematic diagram of the study designs of the animal models              
A Experimental osteoporosis B Experimental rickets  
 
 
3 MATERIALS AND METHODS  
30 
 
3.2 Methods 
 
Table 2 Overview of the applied methods  
 
Paper Animal models Methods 
I Experimental osteoporosis: 
ovariectomy and vitamin D 
deficiency 
 
Bone repair: tibia midshaft fracture 
Immunoassays for serum analyses (25OHD, 
estradiol) 
 
DXA in vivo for BMD measurements  
 
Cantilever bending test  
 
Bone histomorphometry  
II Experimental osteoporosis: 
ovariectomy and vitamin D 
deficiency 
 
Experimental rickets: low 
phosphate and vitamin D deficiency 
rickets and healing from the 
condition for 48h and 72h 
Histology: experimental rickets 
 
Immunoassays for serum analyses (TRAP5b, 
CTX-I) 
 
In situ hybridization (TRAP) 
 
Immunolabeling and fluorescence microscopy 
(mTRAP, ELF97) 
 
Immunoelectron microscopy (TRAP) 
 
Semi-quantitative evaluation 
III 3 days old, untreated rats Immunofluorescence confocal microscopy and 
co-localization analyses (TRAP, RANKL, OPG) 
 
Immunoelectron microscopy of thawed 
cryosections (TRAP, RANKL, LAMP1) 
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4 SUMMARY OF RESULTS 
 
4.1  Paper I 
Melhus G*, Solberg LB*, Dimmen S, Madsen JE, Nordsletten L, Reinholt FP. Experimental 
osteoporosis induced by ovariectomy and vitamin D deficient diet does not markedly affect 
fracture healing in rats  
Acta Orthop 2007 Jun;78(3):393-403 *The authors contributed equally to the study 
 
Animals subjected to ovariectomy and vitamin D-depletion (Ovx-D) developed vitamin D-
deficiency and presented serum levels of estradiol in the range of a human postmenopausal 
state. This confirmed a successful accomplishment of the intervention. The Ovx-D animals 
also developed osteopenia compared to the controls (sham) with significantly reduced BV/TV 
in the femur head (p<0.001), and significantly decreased BMD in the trabecular areas (spine 
and femoral neck, p<0.001). A standardized midshaft fracture was induced in the right tibia in 
all animals 12 weeks post ovariectomy and vitamin D-depletion. DXA-analyses at 2, 3 and 6 
weeks post fracture demonstrated significant lower BMD in the right tibia midshaft at 6 
weeks post fracture and in the right femur neck of both groups at all time-points compared 
with the left limb. No differences were detected with respect to BMD or mechanical 
properties of the callus between the two groups in the fractured right limb; however both 
groups presented a high proportion of non-unions. No impairment in bone strength was 
detected in the Ovx-D group compared to sham, except for significant decreased bending 
stiffness in the femur neck in Ovx-D.  Significant weight gain were seen in the Ovx-D vs. 
sham despite pair-feeding (p<0.001), however, normalization for body weight in the 
mechanical test results did not alter the statistical outcome. In conclusion: experimental 
osteoporosis does not affect the BMD or impair the mechanical properties of the fracture 
callus after 6 weeks of healing. 
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4.2 Paper II 
Solberg LB, Brorson SH, Stordalen GA, Bækkevold E, Andersson G, Reinholt FP. Increased 
tartrate-resistant acid phosphatase (TRAP) expression in osteoblasts and osteocytes in 
experimental osteoporosis in rats  
Submitted October 2013 
 
Tartrate-resistant acid phosphatase (TRAP) is a well known osteoclast marker; however, 
osteoblasts and osteocytes close to bone surfaces or intracortical remodeling sites also 
demonstrate TRAP gene and protein expression as well as enzyme activity. The origin and 
function of TRAP in these cells are not known, thus a suggested mechanism is that osteoblasts 
and/or osteocytes engulf osteoclastic TRAP for inactivation to prevent further bone 
resorption. To evaluate whether changes in osteoclast activity could alter TRAP protein 
expression and enzyme activity in osteoblasts and/or osteocytes in vivo, we analyzed two 
experimental rat models with disturbed bone metabolism and increased osteoclast activity: the 
ovariectomized and vitamin D-depleted rat (Ovx-D) and rats healing from experimental 
rickets for 48h and 72h (experimental rickets). Osteoblasts and osteocytes close to 
intracortical remodeling sites and bone surfaces demonstrated TRAP, most prominent in 
cancellous bone and in osteocytes in both animal models. Intracellular TRAP was located to 
electron dense vesicles with similar morphological features in both osteoblasts and osteocytes. 
Ovx-D increased osteoclast activity (p<0.001) and ELF97+ osteocytes (p<0.05) in cancellous 
bone, but no corresponding increase was observed in the osteocyte lacunar area. The ratio of 
TRAP+ vesicles to total cytoplasm area in cortical osteoblasts (p<0.01) was also increased. In 
addition, Ovx-D presented increased TRAP mRNA expression in osteocytes, however not 
significant, questioning the hypothesis of endocytosis being the mechanism enhancing TRAP 
protein expression and enzyme activity in osteoblasts and osteocytes. To further address this 
question, rats healing from nutritionally induced low phosphate and vitamin D-deficiency 
rickets (experimental rickets) were analyzed as an alternate model of osteoclast activation. 
Enhanced osteoclast activity was noted in healing rickets after 72h (p<0.05), but no 
differences in TRAP expression were detected in osteoblasts or osteocytes. In conclusion; 
increased osteoclast activity does not affect TRAP expression in osteoblast and osteocytes 
favoring the notion that the observed increase in TRAP protein expression and enzyme 
activity in osteoblasts and osteocytes is due to increased synthesis rather than being a result of 
increased osteoclast activity.  
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4.3 Paper III 
Solberg LB, Stang E, Brorson SH, Andersson G, Reinholt FP. Co-localization of tartrate-
resistant acid phosphatase (TRAP) and receptor activator of NFKB ligand (RANKL) in 
lysosomal associated membrane protein 1 (LAMP1) positive vesicles in osteoblasts and 
osteocytes in rats 
Manuscript November 2013 
 
Tartrate-resistant acid phosphatase (TRAP) gene and protein expression as well as enzyme 
activity have previously been observed in osteoclasts, osteoblasts and osteocytes in bone 
tissue in vivo in addition to some reports on TRAP gene expression in hypertrophic 
chondrocytes. Paper II demonstrates enhanced level of TRAP+ osteocytes and TRAP located 
to intracellular vesicles in osteoblasts and osteocytes in experimental osteoporosis, especially 
abundant in osteocytes and osteoblasts in cancellous bone and close to bone surface and 
intracortical remodeling sites. To further address the function of TRAP in osteoblasts and 
osteocytes, long bones of young growing rats were examined in order to reveal the nature of 
the TRAP+ vesicles. Immunofluorescence confocal microscopy displayed co-localization of 
TRAP with RANKL and OPG in hypertrophic chondrocytes and diaphyseal osteocytes. 
Pearson’s correlation coefficient (PCC) > 0.8 indicated strong co-localization of TRAP with 
RANKL and OPG in hypertrophic chondrocytes as well as in diaphyseal osteocytes. 
Transmission electron microscopy (TEM) of tibia metaphysis and diaphysis demonstrated 
TRAP and RANKL in LAMP1+ electron dense vesicles in osteoblasts and osteocytes and 
also displayed co-localization of TRAP and RANKL in vesicular structures in both cell types. 
These observations support the results obtained by confocal microscopy. Recently, in vitro 
data have been reported on OPG as a traffic regulator for RANKL to LAMP1+ secretory 
lysosomes in osteoblasts and osteocytes serving as temporary storage compartments for 
RANKL. In addition, hypertrophic chondrocytes express RANKL and OPG. We 
demonstrated co-localization of TRAP with RANKL in LAMP1+ vesicles in osteoblasts and 
osteocytes as well as co-localization of TRAP with RANKL and OPG in hypertrophic 
chondrocytes and osteocytes. In conclusion: Our observations of RANKL and LAMP1 in 
TRAP+ vesicles in osteoblasts and osteocytes in vivo indicate that TRAP is located to 
RANKL positive secretory lysosomes in osteoblasts and osteocytes. 
5 GENERAL DISCUSSION  
34 
 
5 GENERAL DISCUSSION 
 
5.1 Methodological considerations 
5.1.1 Animals  
In vivo experiments as well as studies of cell cultures have extended our knowledge on bone 
metabolism and bone repair. New intracellular pathways and mechanisms are often 
discovered in vitro; however, there is also a need to confirm the presence and importance of 
such mechanisms in vivo before carrying out further research that eventually may end up in 
large scale studies of promising new therapeutics. Experimental studies on bone metabolism 
and bone repair in a randomized controlled fashion are difficult to perform in humans, and 
cell culture studies will not let us examine the in vivo aspects, we therefore turned to the 
laboratory rat as model for in vivo experimental studies. The animal models described in this 
thesis have previously been shown to be useful for studying different aspects of bone tissue 
properties and are published by other associated member of our group [121-126]. 
Rats are widely used in bone research and their anatomy and physiology are well 
known. In addition, they are easy to house, low at cost and numerous experiments have been 
carried out in bone making the comparison between different studies easy. However, the use 
of rats in experimental bone research do have some limitations: rodent bone structure is more 
primitive than in humans, lacking Haversian systems in cortical bone and intracortical 
remodeling in young rodents are carried out in resorption cavities [127]. This process shows 
similarities with the Haversian remodeling occurring after fracture healing in humans, and the 
use of rats in studies of bone repair has been accepted [128] as long as the limitations are 
taken into account when extrapolating the results to humans. The lack of Haversian systems 
may also be a potential drawback when inducing osteoporosis in rats, as cortical porosity in 
human osteoporosis is due to increased Haversian remodeling. However, the induction of 
osteoporosis in rats by surgical ovariectomy leads to a condition similar to the rapid bone loss 
observed right after menopause in human females [129]; cancellous bone mass at discrete 
sites exhibits an increased rate of bone remodeling and an altered balance between resorption 
and formation occurs. This favors resorption with trabecular thinning and cancellous bone 
loss, while in cortical bone the mid-diaphyseal diameter increases by periosteal growth as 
well as endosteal thinning. The net result is enlargement of the medullary cavity which may 
be observed at earliest between 90 and 120 days after ovariectomy [130]. An additional 
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difference between human and rat bone biology is the persistent longitudinal long bone 
growth with late closure of the growth plates occuring in rats: they reach their sexual maturity 
at the age of 2.5 months and their peak bone mass and skeletal maturity at 10 months. 
However, some of the epiphyseal growth plates remain open after this; in male rats the 
epiphyses of long bones stay open until past 30 months, while in female rats the proximal 
tibia epiphyses close at 15 months [129]. This makes it mandatory to use a control group to be 
able to differentiate the gain or loss of bone mass from the natural bone modeling, and to be 
aware of the growth and maturation rate for the discrete skeletal sites evaluated. Furthermore, 
ovariectomized rats are not prone to fragility fractures, which is the main symptom of human 
osteoporosis. Fragility fractures or spontaneous fractures have actually never been reproduced 
in any animal model. The WHOs definition of osteoporosis, i.e. BMD below 2.5 SDs of the 
reference group with or without fractures, might be used in animal models. Moreover, WHO 
has accepted the osteopenic rat without fragility fractures appropriate for osteoporosis 
research [129]. Also guidelines from the Food and Drug Administration in the US (FDA) 
support this notion by recommending the ovariectomized rat as one out of 2 animal models 
(the other being a large animal model) for studying the effect of drugs affecting 
postmenopausal osteoporosis in proximal tibia, distal femur and lumbar vertebrae [131].   
 
5.1.2  The experimental osteoporosis model 
We induced experimental osteoporosis by a combination of ovariectomy and vitamin D 
deficiency (Ovx-D) in young female rats. The ovariectomy model was chosen following the 
reasoning above and in trying to come even closer in mimicking human postmenopausal 
osteoporosis, vitamin D depletion was introduced to the ovariectomized rats as low levels of 
vitamin D have been associated with increased risk of hip fractures [87, 132]. In addition, the 
model has previously demonstrated reduced mechanical strength of the femur neck [124]. 
Young, skeletal immature rats with a control group were chosen to be sure that an eventual 
delay in the fracture healing process was due to osteoporosis and not to aging which is known 
to impair the healing properties [133-135]. Pair-feeding was introduced to the Ovx-D animals 
in order to prevent the weight gain known to occur in ovariectomized rats [136] (reviewed in 
[137]), however, despite pair-feeding the Ovx-D animals gained significantly more weight 
than the sham animals. This could, at least to some extent, counteract the bone loss induced 
by ovariectomy. On the other hand, normalizing for body weight differences in the 
mechanical test results did not alter the statistical outcome.  
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5.1.3 The experimental fracture model 
The tibia mid-shaft fracture model in rats has been widely used by associated members of our 
group [121, 122, 125, 126] and standardization with respect to fracture site and stabilization is 
well established. However, the sparsely and slowly developing cortical bone loss known to 
occur in the ovariectomized rat [138] may question the chosen mid-diaphyseal fracture: a 
metaphyseal fracture location might have been a better choice as human osteoporotic fractures 
are most frequently located to sites with high degrees of cancellous bone (as the spine, hip, 
distal forearm and proximal humerus). On the other hand, the main purpose of the study was 
to investigate fracture healing and the biomechanical properties of the callus rather than the 
biomechanical strength of long bone diaphyses in experimental osteoporosis. Assuming that 
the systemic effects of ovariectomy and vitamin D depletion on callus formation are 
independent of the fracture site and following the reasoning above, we determined the tibia 
mid-diaphyseal fracture model suitable for the study.  
It is well known that the immobilization and fixation of the fracture site influence the 
degree of callus formation and the mode of fracture healing i.e. intramembranous or direct 
fracture healing vs. endochondral or indirect fracture healing (see 1.6.2. for details). It is 
therefore particularly important to be able to control the standardization and biomechanical 
properties of the fixation in studies of fracture healing. In our study the tibia fracture was 
stabilized with an intramedullary pin. According to a recent review [128], the applied 
stabilization method is judged both easy and reproducible. However, the method lacks 
rotational and axial stability and has a high risk for dislocations. Thus it is no longer 
recommended, as new improved, specially designed rodent implants have been made 
available during the last years. This was not the case at the time our study was carried out and 
the axial and rotational movement between the fracture-ends might have influenced the results 
by leading to the high degree of non-unions observed (45% vs. 36% non-unions in the Ovx-D 
and sham group, respectively). The non-unions were excluded from the mechanical testing, 
however, the remaining number of animals (6 and 7) were still sufficient to allow detection of 
a 20% difference in means [139].  
 
5.1.4 Rats healing from low phosphate and vitamin D-deficiency rickets 
Low phosphate and vitamin D-deficiency rickets as well as healing from the condition has 
previously been used for the study of chondroclasts/osteoclast resorption activity [140] and 
activation in rats [123]. Vitamin D-deficiency and low phosphate concentrations induce 
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rickets with well known morphological changes; inadequate calcification of the growth plate 
region with impaired hypertrophic chondrocyte apoptosis and minimal cartilage resorption 
result in the characteristic widening of the growth plate. The adjacent metaphysis and cortical 
bone also fail to mineralize properly (reviewed in [141]). Inadequacy in the circulating 
mineral concentration as well as reduced transcription of osteopontin [46, 142, 143] as a result 
of the vitamin D deficiency may contribute to the defect mineralization and the subsequent 
failure in resorption. The theory behind this is that the chondroclasts/osteoclasts recruited to 
areas in need for resorption fail to develop appropriate resorption machinery [140] with 
impaired polarization and ruffled border development. This might be due to the inappropriate 
ECM-cell interaction which seems to be essential for the correct development of ruffled 
border (i.e. the lack of osteopontin and defect binding to αvβ3-integrins [30, 31]). However, 
the exact mechanism remains to be set. Nevertheless, reintroduction of vitamin D and 
phosphate to the diet normalize the growth plate region by stimulating cartilage and bone 
mineralization, as well as increasing the chondroclast/osteoclast activity and resorption [123]. 
We confirmed the intended increase in chondroclast/osteoclast activity in our study by 
morphological examination of the growth plate region and by measuring the serum levels of 
TRAP 5b and CTX-I, widely used to determine osteoclast number and activity, respectively 
[144]. To be sure that we determined the true osteoclast activity and that the results were not 
influenced by e.g. differences in bone size; we calculated the ratio of osteoclast activity 
(CTX-I) over osteoclast number (TRAP5b) in the experimental rickets model. This is in 
parallel to estimating osteoclast activity by calculating the ratio of osteoclasts number per 
bone surface (N.Oc/B.Pm) vs. total number of osteoclasts (N.Oc/T.Ar) [145] as performed for 
the Ovx-D rats. 
 
5.1.5 The applied methods  
Dual energy x-ray absorptiometry and bone mineral density  
A keystone in non-invasive monitoring of bone mass and prediction of fracture risk in vivo is 
the assessment of BMD by dual energy x-ray absorptiometry (DXA) measurements. BMD is 
not a measure of true volumetric bone density but rather a measure of mass per area. 
Therefore, some scientists recommend the use of 3-dimensional tools such as pQCT or μCT 
to obtain detailed images of the bone structure and thus allow differing between e.g. cortical 
and trabecular bone [129, 146], however, the limited accessibility of such hardware has 
previously made it difficult to use pQCT or μCT for in vivo measurements. In the first study 
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BMD was used for the evaluation of bone loss and fracture repair by repeated in vivo 
measurements of the animals pre fracture and at 2, 3 and 6 weeks post fracture. By using 
Lunar PIXImus (Lunar, Madison, Wisconsin, USA), specially designed for the assessment of 
BMD in small animals, we were able to perform the measurements in vivo during the healing 
process and thereby reducing the amount of animals needed for the study and/or increased the 
observation time-points.  
 
Mechanical testing  
Mechanical testing ex vivo is used to monitor fracture healing in order to evaluate the different 
biomechanical properties of the callus area. Several types of mechanical tests have been 
described in the literature, but tension, torsion and bending tests are the most common and 
possessing different advantages/disadvantages [147, 148]. Tension tests (longitudinal 
deformation of an elastic body that results in its elongation) are suggested to be most useful 
during the initial phases of fracture healing [149, 150]. Although torsion tests (twisting of a 
body by two equal and opposite torques) have the advantages of evaluating mechanical 
properties of the entire healing bone and are capable of indicating the weakest section [149], 
bending tests have proven to be useful and sensitive in evaluating mechanical properties of 
callus in long bones of several animal models, including rats [147, 151]. Bending tests can be 
performed as 3-point or 4-point variants. Three-point testing is the most widely used; it is 
easy to perform and is considered to be a good test for examining the properties of tibia 
fractures [147]. The whole bone is loaded until failure during testing. The drawback is that it 
creates high shear stress near the midsection of the bone. In paper I, a mechanical test capable 
of examining different bone sites was required. The cantilever bending test with a 3-point 
bending for femur shaft in addition to a modified test for the femur neck, has previously been 
reported successful [124] and thus chosen in order to examine the healing tibia fracture as 
well as the intact femur shaft and neck. Unfortunately, the measurements presented large SDs, 
most pronounced in the testing of the callus area, probably due to the lack of stability and 
reproducibility in the fracture fixation. On the other hand, the intact bones also presented 
large SDs and this may, at least in part, be related to the design of the bending test, the test-
machine itself or the operator’s skills. Another test-machine or mechanical test may have 
given more consistent results; a 3-point bending test has the disadvantage of the manual 
positioning of the fulcrum to the callus area which thereby determines the fracture point. This 
may lead to inadequate and less reproducible results and thus a 4-point bending test or a 
torsion test may have been a better choice. Another aspect is the operator’s testing skills as 
5 GENERAL DISCUSSION  
39 
 
well as the orientation of the specimens in the test machine. However, all bending tests were 
performed by the same operators trained in the procedure to minimize this type of bias.   
 
In situ hybridization 
In paper II the amount of osteocytes synthesizing TRAP were analyzed by in situ 
hybridization. This is a reliable method for the morphological localization of mRNA 
transcripts in tissue sections in vivo by a complementary, labeled nucleic acid probe [152]. An 
advantage of in situ hybridization is the spatial resolution of transcript distribution that is 
obtained at the cellular level, and which is not achieved by northern blotting or different PCR 
methods. A disadvantage is that the preparation for the method is tedious and lengthy. The use 
of the sense probe as negative control for the staining procedure has been a common practice, 
however, it has been reported that anti-sense transcripts occur naturally in the tissues which 
may disturb the interpretation of the results. It is therefore preferable to use other genes 
known to have a different expression patterns as controls [152]. However, this was not judged 
to be a problem in our procedure.   
 
Immunohistochemistry  
The principle of all immuno analyses is the detection of antigen epitopes by antibodies which 
recognize and binds to one or more specific area of the epitope. The antibody is then 
visualized by e.g. chromogens, fluorochromes or conjugated gold (for TEM) making it 
accessible for analyses (Fig. 10). The main purpose of immunohistochemistry is to locate 
defined antigens by combining immunolabeling and morphology at the light, confocal or 
electron microscopic level. However, it is important to notice that false-positive as well as 
false-negative labeling may occur. Lack of staining does not exclude the presence of the 
antigen. To control false-positive staining, non-specific labeling with immunoglobulins (IgG) 
is commonly used together with the secondary antibody or just the solely secondary antibody. 
However, the best available method is labeling of sections known to be devoid of the target 
antigen [153], although, this is not always possible. In our studies we used non-specific IgG 
as well as the solely secondary antibody to control false-positive labeling. Although, it is 
difficult to control false-negative labeling; tissue sections known to be positive for the target 
antigen, e.g. TRAP in osteoclasts, were used to ensure proper antibody labeling. 
 An additional problem to be aware of when labeling for two or more different 
antibodies at the same time, is cross-reactivity between the antibodies, especially if the 
antibodies are raised in the same animal species. If antibodies from different animal species 
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are used for the double labeling, these are usually easily distinguished by species-specific 
immunoglobulins [154]. However, it is always important to control for cross-reactivity by 
single labeling for each of the antibody to ensure the labeling pattern before dual labeling is 
performed. We performed single labeling for every antibody subjected to dual labeling in 
paper III.  
 
 
Fig. 10 Schematic drawing of the 
antigen-antibody interaction 
visualized by protein A conjugated 
gold particle. 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue preparation with chemical fixatives 
Several steps during tissue fixation and preparation may influence the degree of antigen 
labeling; e.g. in vivo or in vitro pre-fixation, post-fixation, decalcification of bone tissue, 
embedding, sectioning and eventually the labeling procedure. Chemical treatment may mask 
epitopes and lower the antigenicity in addition to change the ratio of available epitopes 
between the different tissue compartments. Tissue fixed without or with limited use of 
chemical fixatives are closer to “nature” and have a higher degree of available epitopes, 
although, they are often more unstable to work with. In a previous published paper [155] we 
looked into the effect of a chemical fixative, paraformaldehyde (PF), on bone tissue and 
studied the effect of antigen retrieval by heating in order to further improve the immunogold 
signal. In addition, we compared the PF fixed tissue with high-pressure freezing and freeze-
substitution (HPF-FS), a procedure with limited subjection to aldehyde fixation and 
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considered to be the “gold standard” for optimal preservation of tissue for ultrastructural 
examination [156-158]. PF fixed tissue, which is known to induce cross-links between the 
fixative and the tissue proteins [159] masking the epitopes, showed significantly enhanced 
immunogold signal in the retrieved sections, probably due to the breakage of the covalent 
bonds between PF and the tissue proteins. Retrieval of the HPF-FS stabilized sections did not 
increase the immunogold signal, extending the experience by others [160-163]. Interestingly, 
we observed that retrieval by heating altered the tissue distribution pattern of the epitopes in 
the PF fixed sections compared with the non-retrieved PF sections and the sections stabilized 
by HPF-FS. Thus, the results indicate that antigen retrieval by heating may distort the 
distribution pattern of the immunogold signal and that retrieval, at least by heating, should be 
performed with care. And as s a consequence, antigen retrieval was not used in our 
subsequent studies. 
 
Tissue preparation for electron microscopy  
Electron microscopy is very useful for the examination of morphological features and antigen 
labeling at high resolutions. However, cutting of ultrathin decalcified bone sections suitable 
for electron microscopic examination requires in most cases pre-sectional embedding in a 
resin. Acrylic resins have traditionally been preferred for ultrastructural immunolabeling 
compared to conventional epoxy resins [162, 164, 165] due to their combination of sustained 
immunity as well as stability. In contrast to epoxy resins forming covalent bonds with the 
tissue proteins, acrylic resins do not copolymerize with the proteins but rather surround the 
tissue structures making the antigens more prone to labeling after sectioning as the knife-edge 
cut between the tissue and the resin. However, an alternate method may increase the 
immunolabeling even more; thawed cryosectioning [166, 167] introduces only a limited 
degree of aldehyde fixation to the tissue before embedding in sucrose (to avoid crystal 
formation) and subsequent freezing in liquid nitrogen. Thus, the minimal tissue interaction 
increases the success-rate for intracellular immunogold labeling and made us able to do 
further morphological characteristics of the observed intracellular TRAP+ vesicles in paper 
III.  
 
Histomorphometric evaluations  
Bone histomorphometry was performed to quantify gene and protein expression, enzyme 
activity as well as number of cells and amount of bone areas in groups subjected to different 
interventions and to allow comparisons between groups. The analyses were preformed 
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according to stereological principles [168] using a semiautomatic interactive image analyzer 
program and the sections were coded for the examiner in all cases. Stereological 
nomenclature was used in paper I, while the suggested nomenclature from the American 
Society for Bone and Mineral Research [169] was followed in paper II and III.  
Histomorphometry is a powerful tool to quantitate morphological differences in the 
tissue between differently treated specimens. However, it is important to be aware of pitfalls 
when interpreting the sampled data. In addition, one of the “axioms” in histological evaluation 
and histomorphometry is that “your histomorphometry is just as good as your histology” 
[170] and proper tissue fixation and embedding are therefore highly important: the procedures 
should be carried out in light of subsequent analyses to ensure equal treatment of the tissue 
specimen in the different groups subjected to examination. We used histomorphometry to a 
large extent in our studies both for the quantification of amount or size of bone structures, 
bone cells and cell compartments (paper I, II) and for the quantification of the amount of 
antigen presented in different bone areas and cell compartments (paper II). The first is rather 
uncontroversial as commonly defined structures are measured; however, it is important to be 
accurate and randomize the sample areas due to stereological and histomorphometric 
principles. The quantification of antigens by antibody labeling in different compartments and 
specimens is more controversial. The antigen labeling is confounded by false-positive and 
false-negative labeling as it is difficult to treat the bone tissue identically in every step during 
the preparation and several steps may interfere with the available number of epitopes [153]. 
However, the combination of different methods detecting the same antigen may make up for 
some of the confounders. In paper II, the distribution of TRAP in bone cells was evaluated 
using histomorphometry and the results compared between animals with different bone 
phenotypes. Several methods including in situ hybridization, immunofluorescence and 
fluorescence microscopy as well as immunogold labeling and electron microscopy were 
performed on the same type of bone tissue in order to minimize the effect of false-positive 
and false-negative labeling. Large standard deviations were demonstrated between the groups 
in the differently applied methods, which may reflect some of the problems discussed above, 
although biological variations among the animals can also be part of the reason. However, the 
results taken together favor that osteoblasts and osteocytes in Ovx-D animals express more 
TRAP than such cells in sham animals making the conclusion more reliable. 
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Confocal microscopy and co-localization analyses 
The observation of co-localization between antigens provides solid support for their 
interference; however, it is important to notice that co-localization does not directly prove 
their functional relationship. Visual co-localization is strongly supported by quantitative co-
localization analyses comparing the signal in the same pixel location between multi-channel 
fluorescence images [171] (reviewed in [172]). With immunofluorescence confocal 
microscopy, one on the advantages is the opportunity to do quantitative co-localization 
analyses between differently labeled antigens using semi-automatic software specially 
designed for such analyses. However, the tissue sections and the images have to be treated 
properly in order to get reliable results from the co-localization analyses. A confocal 
microscope improves the possibility for quantitative co-localization analyses as the lasers scan 
the tissue labeled with different fluorochromes with narrow wave length using the optimized 
emission filters. In addition, the lasers scan sequentially through the chosen area one-by-one, 
and together with the narrow wave length, this approach minimizes the bleed-through of the 
different fluorochromes between the channels. In order to be sure that there really is true co-
localization in a three-dimensional (3D) way and not only a coincidental two-dimensional 
(2D) overlap, z-stacks should be performed allowing images to be obtained through the tissue 
section. In this way it is possible to perform the co-localization analyses in 3D along the x, y 
and z-axis. The results of the analyses and the calculations may be presented as different 
coefficients; Pearson’s correlation coefficient (PCC) is among these and is commonly used to 
determine co-localization as it measure the strength of a linear relationship between 2 
variables [171], (reviewed in [172]). In paper III semi-automatic quantitative co-localization 
analyses were performed on 2D images using Coloc2 (Fiji, ImageJ) and the results were 
presented as PCCs. In addition, z-stacks were obtained of the actual cells and tissue sections 
demonstrating visual 3D co-localization between the different antigens.  
 
5.1.6 Statistics  
The statistical analyses were performed in SPSS 12.01 (I) and PASW Statistics 18 (III) for 
Windows (Microsoft Corporation). Although, the analyses of the mechanical data in paper I 
differed slightly from a true Gaussian distribution, a two-tailed independent-sample t-test was 
found suitable for the analyses after discussion with an independent statistician (Betina Kulle, 
Department of Biostatistics, University of Oslo, Norway, personal communication). In paper 
II we chose nonparametric tests for two and k variables (Mann-Whitney and Kruskali-Wallis, 
respectively) for the semi-quantitative analyses, as they are less likely to have a Gaussian 
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distribution and to give maximum protection against type I errors. For the measured data we 
chose parametric tests; Student’s t-test for two variables and one-way analyses of variance 
(ANOVA) for k variables, as measured data are more likely to have a Gaussian distribution. 
All results were given as means and standard deviations (SD) (paper I, II) with statistical p-
values and sample sizes. A p-value of < 0.05 was considered significant. In paper III 
Pearson’s correlation coefficient (PCC) above threshold was calculated using Coloc2 (Fiji, 
ImageJ) to determine the co-localization of 2 different antibodies. Positive co-localization was 
considered with PCC > 0.8. 
 
5.2 Discussion of main results 
5.2.1  Paper I 
The experimental osteoporosis model in female rats was successfully accomplished with 
undetectable serum levels of 25(OH)D in 94% of the Ovx-D rats and below the human 
defined deficiency level in all rats [173], in addition to estradiol levels below the human 
postmenopausal state. The Ovx-D rats developed an osteopenic phenotype with significantly 
reduced BMD in bone areas with a high content of cancellous bone; however, no cortical 
bone loss (i.e. increased medullary cavity) was observed. This may be due to the  relatively 
short time-span after ovariectomy (~70 days) [130] and is in line with the observed pattern in 
the classic ovariectomized (OVX) rat model [146]. In addition, except for significantly 
decreased bending stiffness in the Ovx-D group, no impaired biomechanical properties were 
detected in the femur neck or long bone diaphyses. Thus we failed to reproduce the 
weakening of the femur neck as previously reported in this model [124]. However, based on 
our results and sample size it is unlikely that an undetected but clinically relevant difference 
in mechanical strength is present in the femoral neck in the Ovx-D rats at the tested time-
point. 
 
Experimental osteoporosis and the mechanical properties of the callus 
Old osteoporotic ladies heal from a femur shaft fracture more slowly than young men [174], 
however, whether this is due to the osteoporosis or the age is not answered by Nikolaou and 
co-workers. Investigating the fracture healing capacity in osteoporotic humans is difficult and 
there are still no reports on the fracture healing capacity in osteoporotic men or women 
compared to sex and age-matched, healthy controls. On the other hand, several experimental 
studies on animals have been performed over the last 15 years using the classic OVX model 
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in the rat, with or without dietary interventions [62, 133, 175-189], trying to address the 
question; does osteoporosis delay fracture healing? However, the results conflict in BMD and 
mechanical properties of the fracture callus both at early and late healing (defined as < 6 
weeks and > 6 weeks, respectively) regardless of the age of the animals at the fracture time-
point. Studies which demonstrated decreased healing capacity in the OVX group [133, 175-
177, 181, 188] also reported symptoms of delayed healing at the histological level with 
architectural distortion, decreased mineralization and increased osteoclast number [175-177, 
181]. Extended examination of the fracture calluses from the animals in paper I by Melhus 
and co-workers [62] showed no such difference according to the well known bone remodeling 
markers OPN, BSP, TRAP and cathepsin K as well as the osteoblast and osteoclast number. 
However, they found less connective and fibrous tissue and more cartilage and woven bone at 
3 weeks of healing in the Ovx-D animals compared to sham. Similar results have also been 
reported by others and might indicate an impact of osteoporosis on endochondral bone 
formation in the early period of fracture healing [177, 181, 184, 185, 190]. In our model these 
differences were undetectable after 6 weeks [62].  
 
Vitamin D, bone strength and fracture healing 
Interestingly, our data indicate that the additive effect of vitamin D depletion does not 
dramatically alter the results reported from OVX rats on normal rat chow or OVX rats fed a 
low calcium diet (LCD) [178, 182, 183, 187]. Vitamin D-deficiency is common among the 
human female osteoporotic population [191] and insufficient levels of vitamin D have been 
reported in osteoporotic patients experiencing a hip fracture [87, 132]. In addition, 1,25D 
administered orally to OVX rats has resulted in increased fracture callus strength and callus 
remodeling capacity compared to controls both at 6 and 16 weeks post fracture [192]. Thus it 
is tempting to assume that the opposite would be the case in a vitamin D deficient state; 
however, such conclusions cannot be drawn. Moreover, a recent study failed to show any 
difference in the serum levels of 25(OH)D during fracture healing in individuals suffering 
from a fragility fracture and low BMD vs. age matched controls with fracture and normal 
BMD, however, no control group without fracture was included [193]. In both groups the 
serum level of 25(OH)D was in the range of low (<20ng/mL) as defined by experts [173, 
191], and it could not be excluded that low serum level of 25(OH)D makes the individual 
more prone to fracture regardless of BMD.  
Vitamin D favors phosphate and calcium absorption from the intestine as well as the 
reabsorption of phosphate from the kidneys. On the other hand, vitamin D-deficiency is 
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followed by impaired mineralization of osteoid, which seems to be mostly dependent on the 
circulating ion levels of calcium and phosphate. Studies have shown that animals with dietary 
induced vitamin D deficiency do not develop osteomalacia as long as the levels of calcium 
and/or phosphate are kept within the normal range [194, 195]. This implies that the impact of 
the dietary induced vitamin D-deficiency in our rats may have been overridden by the normal 
amount of calcium and phosphate in the diet, thus with little or no impact on the callus and 
skeletal mineralization.   
 
Limitations 
Among the limitations in paper I are the low healing rates, large SDs in mechanical test 
results as well as the failure to reproduce the weakening of the femoral neck as previously 
reported.  The low healing rate and the high variance in the measured callus strength, indicate 
lack of success in inducing reproducible fractures with subsequent standardized group-
dependent healing as mentioned above. A larger sample size for biomechanical testing may 
have reduced the impact of this variation; however, fixation of a tibia mid-shaft fracture with 
an un-locked intramedullary pin is not a stable situation and it is likely that the large SDs 
observed in the mechanical testing of the callus still would have been present. Furthermore, it 
is known that immobilization can reduce or delay fracture healing in mice [196]. This is at 
least in part supported by the left-right comparison in our study showing decreased BMD of 
the right (fractured) limb in both groups. Thus, the use of another type of osteosynthesis may 
have been more optimal to secure a stable situation and thereby reduce the impact of 
immobilization on the fracture callus.  
Rodent strains have shown differences in their fracture healing capacity [128] and the 
chosen rat strain could therefore also be a confounder. Most of the models on fracture repair 
in OVX rats have been carried out in Sprague-Dawley rats [133, 175, 178, 181-184, 186]. On 
the other hand, Wistar rats (as we used) are represented in both groups favoring altered [176, 
185] or unaltered [179, 187] fracture healing capacity. The strain used in this case is thus a 
less likely contributor since the failure in reproducing the weakening of the femur neck [124] 
may have been due to the variance in genetic background of the Wistar rats.   
 
5.2.2  Paper II & III 
TRAP in osteoblasts and osteocytes 
TRAP is well known as an osteoclast marker and is present in the resorption lacunae as well 
as in transcytotic intracellular vesicles during active bone resorption [35, 62, 123, 140, 197]. 
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The presence of osteoclastic TRAP in the resorption lacuna makes the enzyme available for 
interaction with other bone cells. In addition, it is also reported that osteoblasts and osteocytes 
expressing TRAP are observed in the metaphysis and in cortical bone close to intracortical 
remodeling sites as well as at the endosteal and periosteal surfaces [110, 113, 116]. These are 
all bone sites close to or under active remodeling and there have been hypothesized that 
TRAP in osteoblasts and osteocytes is somehow related to osteoclast activity [110, 113, 114, 
116, 118]. 
The main purpose of the study in paper II was therefore to test whether enhanced 
osteoclast activity in vivo would result in a subsequent increase in TRAP in osteoblasts and 
osteocytes. The theoretical background for this hypothesis is supported by the in vitro 
observations from Perez-Amodio and co-workers [114, 115]: They reported that osteoblasts-
like cells co-cultured with osteoclasts precursors are able to remove TRAP from the medium 
and subsequently inactivate it. In addition, TRAP has been suggested as one of the factors 
coupling bone resorption to bone formation [14, 118] as immature osteoblasts, when cultured 
in the osteoclast lacuna in vitro, rapidly differentiate into a mature, bone-forming phenotype. 
Osteoblast endocytosis may be a central event in both theories.  
 
The effect of ovariectomy and vitamin D depletion 
The Ovx-D rats developed osteopenia as discussed above, and we demonstrated increased 
osteoclast activity in the Ovx-D rats compared with sham, as anticipated. The increase in 
osteoclast activity may be due to the estrogen withdrawal, as in menopause or after 
ovariectomy in fertile women. Estrogen deficiency diminishes osteoclast apoptosis by down  
regulation of MMP3 and cleavage of FASLG [58] in osteoblasts. In addition, removal of the 
protective anti-oxidative effect of estrogen on osteoblasts and osteocytes is suggested to 
increase osteoblast and osteocyte apoptosis leading to enhanced RANKL secretion by the 
same or neighboring cells [19, 20, 56, 198, 199]. It is also suggested that osteocyte apoptosis 
directs osteoclasts to bone areas in need for resorption [56]. These effects result in increased 
osteoclast life-span and activity as well as decreased number and bone-forming activity of 
osteoblast altering the balance between bone resorption and bone formation with a net bone 
loss as an end result. With normal levels of calcium and phosphate in the diet, adding vitamin 
D deficiency to the OVX model would probably not affect the mineralization of osteoid. Thus 
the increased osteoclast activity observed in the Ovx-D rats was most likely due to estrogen 
deficiency rather than low levels of vitamin D.  
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The Ovx-D rats demonstrated increased levels of TRAP+ vesicles in osteoblasts and 
osteocytes vs. sham in cortical bone, increased levels of TRAP enzyme activity in cancellous 
bone as well as a tendency to increased levels of TRAP enzyme activity in cortical bone (not 
significant). The observed increase in TRAP+ vesicles could be explained by the endocytosis 
theory, however, the increase in TRAP enzyme activity is somewhat more difficult to explain; 
engulfing TRAP for inactivation is not logically linked with up-regulation of the enzyme 
activity. On the other hand, Perez-Amodio and co-workers also demonstrated increased TRAP 
enzyme activity in their co-cultured osteoblasts with a subsequent rapid decrease in the 
activity, suggesting that this might be due to increased activation of an endogenous fraction 
[114]. In line with this observation, endocytosed and subsequently activated TRAP could play 
a role as a coupling factor promoting osteoblast maturation and activation as suggested by 
Sheu and co-workers [118]. This notion is further supported by Gradin and co-workers [112] 
who demonstrated increased cortical bone formation as well as osteoblast maturation and 
differentiation in transgenic mice over-expressing TRAP in osteoblasts. However, this theory 
does not explain why osteocytes engulf TRAP. Moreover, examining the bone sections for 
TRAP mRNA and monomeric, uncleaved TRAP (mTRAP) displayed a tendency to enhanced 
levels of these products in osteocytes in the Ovx-D animals, questioning endocytosis as the 
main mechanism for the observed increase in TRAP+ vesicles and TRAP enzyme activity in 
the Ovx-D rats. Thus, the results called for a second “osteoclast activation” model to address 
the question in some more depth.  
 
The effect of low phosphate and vitamin D deficiency rickets and repletion 
Nutritionally induced vitamin D-deficiency together with low levels of phosphate causes 
rickets and/or osteomalacia with well known morphological changes [123, 140]. Repletion of 
vitamin D and phosphate stimulates proper mineralization of cartilage and osteoid which in 
turn leads to activation of chondroclasts/osteoclasts. In addition, high doses of vitamin D 
stimulate RANKL transcription and osteoclastogenesis directly through activation of 
VDR/RXR receptor complex in growth plate chondrocytes, osteoblasts and osteocytes [47, 
48, 200]. Increased osteoclast activity was observed in rats healing from dietary induced low 
phosphate and vitamin D-deficiency rickets, as expected, with the highest rate of osteoclast 
activity, expressed by the CTX/TRAP5b ratio, in healing after 72h. Although all of the groups 
in the experimental rickets model displayed osteocytes and osteoblasts with TRAP+ vesicles 
in cancellous bone and TRAP enzyme activity in osteocytes in cancellous and cortical bone, 
no differences were demonstrated between the groups in the experimental rickets model 
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regarding TRAP in osteoblasts and osteocytes, despite increased osteoclast activity in healing 
after 72h. TRAP mRNA was not detected in osteocytes in cortical bone in any of the groups, 
and though mTRAP was present in all groups in both cancellous and cortical bone indicating 
TRAP synthesis and translation to protein, there were no differences between the groups. 
Thus, osteoclasts are less likely the main source of TRAP in osteoblasts or osteocytes in vivo 
neither in experimental osteoporosis nor in experimental rickets and the endocytosis theory is 
not supported by the results in paper II.   
 
TRAP+ vesicles in osteoblast and osteocytes 
The morphological distribution of TRAP in osteocytes and osteoblasts is only sparsely 
described in the literature: Bonucci and co-workers demonstrated TRAP reaction product in 
vesicular structures in osteoblasts from calcium-depleted rats [111], Yamamoto and Nagai 
described TRAP reaction product in the different components of the Golgi complex and 
structures suggested to be secretory lysosomes in osteoblasts [116] and Reinholt and co-
workers observed TRAP+ vesicles in osteoblast-like cells using immunogold technique [201]. 
We examined bone sections from the experimental osteoporosis and rickets models in paper II 
as well as bone sections from young, growing rats in paper III using transmission electron 
microscopy (TEM) and observed TRAP in electron dense vesicles with similar features in 
osteoblasts and osteocytes in both cancellous and cortical bone. The TRAP+ vesicles in 
osteoblasts and osteocytes do to some extent differ from the intracellular TRAP+ vesicles 
observed in osteoclasts [140, 201].  However, TRAP+ vesicles postulated to be secretory 
lysosomes with regulated secretion have been described in osteoclasts [202] and the vesicles 
presented by van Meel and co-workers [202] do have a similar appearance as the TRAP+ 
vesicles we observed in osteoblasts and osteocytes. From their morphological appearance may 
represent late endosomes or secretory lysosomes involved in intracellular transport, cell 
communication or in local bone resorption. However, we did not find any support for the 
latter in paper II. This is in line with the results of Qing and co-workers on unloaded bone and 
it seems like osteocytic bone remodeling is only present under specific conditions with 
excessive requirements for calcium and phosphate, as in lactation [21]. However, also direct 
sclerostin treatment on osteocytes in vitro has demonstrated increased osteocyte lacunar area 
and although the study also demonstrated enhanced levels of TRAP and cathepsin K in the 
osteocytes, only carbonic anhydrase (CA2) was demonstrated to have an direct effect on the 
osteocytic osteolysis, as the CA2 inhibitor, acetozolamide prevented the increase in the 
osteocyte lacunar area [203]. This indicate that TRAP may have a role in osteocytic 
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osteolysis, but do not prove it as inhibition of TRAP or cathepsin K was not tested, and TRAP 
may also have an additional role in both osteoblasts and osteocytes.  
Semi-quantitative calculations demonstrated increased level of TRAP+ vesicles 
relative to total cytoplasmic area in osteocytes compared to osteoblast in all animals, as well 
as in cancellous vs. cortical bone in the experimental rickets model. The latter was also 
observed for TRAP enzyme activity in all groups favoring a role for TRAP in bone 
remodeling; there is an obvious structural difference between cancellous and cortical bone 
and cancellous bone appears to be more metabolic active than cortical bone with a higher 
bone turnover. This might be explained by a greater surface to volume ratio in cancellous vs. 
cortical bone [204] and the increase in TRAP+ vesicles and enzyme activity in osteoblasts and 
osteocytes in cancellous bone might therefore be linked to bone turnover, however, the 
mechanism remains elusive.  
 
Co-localization of TRAP and RANKL in LAMP1+ vesicles 
Lysosomal associated membrane protein 1 (LAMP1) is known to be present in membranes of 
late endosomes and lysosomal compartments protecting the membrane from auto-digestion 
(reviewed in [205]). Generally, late endosomes and lysosomes are considered to be degrative 
organelles where lysosomes represent the end-stage on the endocytotic route degrading 
endocytosed material. Different subclasses of these organelles do however exist and both late 
endosomes and lysosomes can function as secretory organelles. Specialized multivesicular 
late endosomes can fuse with the plasma membrane and cause the release of exosomes [206], 
and secretory lysosomes can secrete their contents in response to external stimuli [207]. 
Secretory lysosomes and “ordinary” lysosomes share features such as the presence of 
lysosomal associated membrane proteins and an acidic luminal pH for the function of the acid 
hydrolases stored in their lumen. Secretory lysosomes are, however, specialized as they in 
addition to having a degrading function, serve as organelles for storage of newly synthesized 
secretory proteins and have the ability to fuse with the plasma membrane [208]. Our 
observation of LAMP1 in the TRAP+ vesicle membrane justifies the vesicular appearance, 
however, it does not alone allow a direct determination of the nature of the vesicles; however, 
the co-localization of TRAP with RANKL indicates that the vesicles might be secretory 
lysosomes. The group of Suzuki has performed excessive research on the intracellular 
regulation of RANKL in osteoblast and osteocytes [23, 24, 209, 210] and has demonstrated 
two pathways for RANKL to the cell surface in both osteoblasts and osteocytes in vitro; one 
minor route transporting RANKL directly from the Golgi complex to the cell surface; and one 
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major route requiring both vacuolar sorting protein 33 homolog A (VPS33A) [209] in 
addition to OPG binding to RANKL before the complex is sorted to LAMP1+ secretory 
lysosomes [24]. The major route seems to be the crucial pathway in the regulation of the 
osteoclastogenesis, as a defect in the traffic regulatory activity of OPG increases the 
osteoclastogenic ability in vitro despite increased numbers of OPG decoy receptors [24]. The 
release of RANKL to the cell surface from the secretory lysosomes is suggested to be 
regulated by the binding of RANK at the surface of osteoclast precursors to small amounts of 
RANKL presented at the osteoblast or osteocyte membrane from the minor pathway. This 
will in turn activate Rab27a/b which leads to docking and release of RANKL from the 
secretory lysosomes [23, 210]. Our TEM immunogold analyses indicate that the TRAP+ 
vesicles with co-labeling of both RANKL and LAMP1 in osteoblasts and osteocytes in vivo, 
are similar to the secretory lysosomes described as storage compartments for RANKL by the 
group of Suzuki. This notion is further supported by the immunofluorescence co-localization 
analyses for both TRAP/RANKL and TRAP/OPG in diaphyseal osteocytes which revealed 
strong co-localization between the antibodies, as OPG has been described as a traffic 
regulator for RANKL from the Golgi complex to the secretory lysosomes [24]. The data may 
imply a role for TRAP in the secretory lysosomes, which is not unlikely as TRAP is an acid 
phosphatase promoting its function in an acidic milieu. However, it cannot be excluded that 
TRAP is released together with RANKL from the secretory lysosomes promoting its function 
outside the cells e.g. as a coupling factor between the osteoclastic bone resorption and the 
osteoblastic bone formation as suggested by Sheu and co-workers [118].   
If the vesicles are secretory lysosomes that secrete their content at the cell surface in 
order to communicate with other cells in e.g. the bone marrow, we would expect them to be 
small enough to travel along the osteocyte canaliculi. Our observed TRAP-RANKL-LAMP1+ 
vesicles are 200-500nm in diameter; You and co-workers [211] have measured osteocyte 
canaliculi in long bone diaphyses from 15 weeks old mice and based on their results we 
propose that it is at least a theoretical possibility for vesicles in the range of 200-500nm in 
diameter to travel along the osteocyte extensions in the canaliculi for secretion. This would 
make the cell-cell communication possible and may explain a way for RANK and membrane-
bound RANKL to interact in order to stimulate osteoclastogenesis.  
In addition to the demonstration of TRAP+ vesicles in osteoblasts and osteocytes we 
observed TRAP in what seems to be vesicular structures in hypertrophic chondrocytes. The 
presence of TRAP in hypertrophic chondrocytes have been reported by others [62], but not 
extensively followed up. RANKL has previously been demonstrated in hypertrophic 
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chondrocytes [8, 20, 212] and also reported located to the same celltype and bone level as 
OPG [212]. We observed RANKL and OPG co-localized with TRAP in hypertrophic 
chondrocytes, suggesting the same mechanisms for TRAP in association with RANKL and 
OPG to be operative in hypertrophic chondrocytes as in osteoblasts and osteocytes.  
The demonstration of loop-TRAP/mTRAP in the Golgi complex in osteoclasts, but not 
in osteoblasts and osteocytes may be related to a limited production, as low levels of synthesis 
are difficult to detect with the immunogold technique. Furthermore, labeling for TRAP was in 
osteoblasts and osteocytes restricted to LAMP1+ electron dense vesicles, no significant 
labeling was observed neither along the synthetic pathway (endoplasmatic retriculum and 
Golgi) nor early in the endocytotic pathway (plasma membrane, early endosomes, 
multivesicular bodies). This may indicate that the technique is not sensitive enough to detect 
small amounts of protein along these pathways, and indirectly supports the assumption that 
the observed labeling of TRAP is localized to secretory lysosomes where newly synthesized 
protein gets stored and thus concentrated to a degree that allows detection.  
 
Limitations 
One of the limitations in paper II is the difference in age, sex and strain in the experimental 
models included; the experimental OP rats were 25 weeks old female Wistar rats, while the 
animals in the experimental rickets model were 10 weeks old male Sprague-Dawley rats. 
However, as the rats were compared within their own model-system and to untreated controls, 
this was not judged to be a confounder. On the other hand, it may explain some of the 
differences observed between the animal models as the male rats were less skeletally matured 
due to age and sex. The controls in the experimental rickets group did not display TRAP+ 
vesicles in cortical osteocytes which differed from the sham animals in the experimental 
osteoporosis model. Extrapolating to TRAP what we know for RANKL, the reason might be 
that the osteoblasts are the most important bone regulator in young individuals, while the 
osteocytes are the most important source of RANKL and the main orchestrator of bone 
remodeling in adults [19, 20]. However, this hypothesis remains to be proven.   
Another limitation in paper II was the difference in result between TRAP mRNA and 
mTRAP, most abundant in the experimental rickets model where no TRAP mRNA was 
detected in the cortical osteocytes, while mTRAP occurred in all groups. This is probably due 
to the difference in sensitivity between in situ hybridization and immunofluorescence 
microscopy rather than differences between synthesis and translation to protein.  
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In paper III the use of a limited number of individuals and at a very young age may 
question the general validity of our results. We do not know if the observed co-localization of 
TRAP with RANKL and OPG in the LAMP1+ vesicles in hypertrophic chondrocytes, 
osteoblasts and osteocytes represent a general mechanism in bone remodeling, and this call 
for further investigation.   
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The experimental osteoporosis model (Ovx-D) was successfully established in rats, 
demonstrating an osteopenic state comparable with the classic rat OVX model implicating 
that the addition of vitamin D deficiency to the model had no major effect. The model failed 
to demonstrate any difference in the fracture callus after 6 weeks of healing evaluated by 
BMD and mechanical testing, thus indicating no difference in fracture healing capacity 
between the Ovx-D and sham rats. However, the model demonstrated increased osteoclast 
activity with a corresponding enhancement of the amount of TRAP located to intracellular 
vesicles in osteoblasts and osteocytes in Ovx-D vs. sham. Similar increases in TRAP were not 
observed in rats with nutritionally induced phosphate and vitamin D-deficiency rickets or 
healing from it, despite excessive osteoclast activity during healing. Taken together with the 
tendency to increased TRAP synthesis in cortical osteocytes in the Ovx-D rats, our results 
indicate an endogenous origin of TRAP in osteoblasts and osteocytes independent of the 
osteoclast activity. Further examination of the TRAP+ vesicles in osteoblasts and osteocytes 
in rat bone tissue demonstrated co-localization of TRAP with RANKL in the vesicles with 
LAMP1 presented in the vesicle membrane. Co-localization of TRAP with RANKL and OPG 
in vesicular structures in osteocytes and hypertrophic chondrocytes was also observed. We 
therefore propose that the TRAP+ vesicles may be secretory lysosomes as RANKL and OPG 
recently have been demonstrated in LAMP1+ secretory lysosomes in vitro. This suggestion 
indicates a new role for TRAP in bone remodeling, e.g. 1) as a regulator of RANKL secretion; 
2) as a contributor to the activation and/or direction of osteoclasts to bone areas in need for 
remodeling; or 3) as a coupling factor promoting osteoblast differentiation released 
simultaneously with the osteoclast stimulator (Fig. 11).  
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Fig. 11 Schematic overview of the hypotheses RANKL, OPG and TRAP are synthesized in 
the osteoblast, osteocyte and hypertrophic chondrocytes. OPG binds to RANKL and the 
complex sorts to LAMP1+ secretory lysosomes (major RANKL secretory route, as suggested 
in [23, 24]). TRAP co-localizes with RANKL in the LAMP1+ vesicular structures and with 
OPG at the cellular level and we therefore propose the following hypothetic functions; 1) 
TRAP interacts with or modifies the RANKL-OPG complex in the secretory lysosomes; 2) 
TRAP is secreted to the ECM where it serves as a co-stimulatory factor for osteoclast 
progenitors (Oc-P); or 3) TRAP is secreted to the ECM where it acts as a differentiation and 
maturation factor for the osteoblast progenitors (Ob-P).  
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7.1 Co-localization of TRAP with RANKL and OPG  
Further analyses are needed to elucidate TRAP’s role in bone remodeling. The observed 
results of TRAP/RANKL and TRAP/OPG co-localization in the 3 days old growing rats need 
to be confirmed in other animal models as well. Observations of the co-localization in other 
models with different sex, age and strain would strengthen the results. The experimental 
osteoporosis model and the experimental rickets model are suitable for such studies in 
addition to their aspects of altered bone metabolism.  
It would also be fruitful to study TRAP in relation to RANKL and OPG in cell 
cultures of osteoblasts and osteocytes by e.g. using the technique described by Uchihashi and 
co-workers [213]. The advantages of cell culture studies are the opportunity to affect protein 
synthesis, compartment localization and protein secretion in different ways in order to further 
elucidate the nature of the TRAP+ vesicles in osteoblasts and osteocytes. Developing 
osteoblast and osteocytes in vitro will hopefully make us able to look into the protein 
regulation using immunofluorescence and confocal microscopic live imaging techniques in 
addition to immunogold and TEM of differently treated cells; e.g., immunogold labeling for 
Rab27a/b [210] as markers for location of TRAP to secretory lysosomes, CD63 as a marker 
for exocytosis, glucocorticoid treatment to induced cell apoptosis among others.  
 
7.2 The effect of estrogen on osteocyte apoptosis and TRAP expression in 
osteocytes as well as on the co-localization of TRAP with RANKL and OPG 
The OVX rat model may be used with estrogen replacement therapy (HRT) in order to 
elucidate the effect of estrogens on osteocytes apoptosis in cortical and cancellous bone with 
focus on TRAP, TRAP/RANKL and TRAP/OPG in these cells. 
 
7.3 The secretion of RANKL from osteoblasts and osteocytes in genetically 
modulated in vivo models 
The knowledge on how RANKL from osteoblasts and osteocytes stimulates the 
osteoclastogenesis still remains elusive. The immunogold technique for TEM on thawed 
cryosections is a powerful tool in order to look for the vesicles in animal models with altered 
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RANKL production e.g. to see if the vesicles might represent the main secretory route for 
RANKL. 
 
7.4 The fracture healing capacity in osteoporosis – a clinical trial with age-
matched healthy controls 
Animal models mimicking human osteoporosis (OP) seems to be suboptimal to answer the 
question whether osteoporosis delays fracture healing properly [214]. In addition, the 
presence of such delay in e.g. the ovariectomized rat does not implicate that this also occurs in 
humans. A limited number of studies regarding the question have been performed in humans 
as far as we know [174, 193] with none directly addressing the fracture healing capacity in 
osteoporotic individuals compared with sex and age-matched controls. We do not know if 
osteoportic fractures heal more slowly or are more prone to non-unions or implant failure than 
fractures healing in healthy individuals, however, the latter is assumed as internal fixation of 
fractures in osteoporic, old individuals is challenging due to their poor bone structure. The 
large number of fragility fractures as well as the possible costs of pro-healing therapeutics in 
the future, justifies a clinical study trying to predict the fracture healing capacity in an 
osteoporotic state.  To achieve reliable results, study design as well as well defined semi-non-
invasive end-points, are critical and, therefore, a pilot study should be perform.  
 The following set up is suggested in brief: inclusion of sex and age-matched 
individuals with similar fracture type/site in need for surgical fixation, age > 40 years (mature 
skeleton, above peak bone mass), DXA at the time of surgery in order to group the patients 
(OP/control). OP as defined by WHO [77] (with or without previous fragility fracture). 
Suggested end-points would be: BMD by DXA or QCT of the callus area at the follow-up 
consultations; healing of the fracture evaluated by CT; failure of fixation within 12 weeks of 
healing; non-union after 12 weeks. Follow-ups: 2/3, 6, 12 and 52 weeks post surgery with 
clinical and radiological examinations (between 12 and 52 weeks control until healing as in 
ordinary fracture care). Interesting parameters to register at the time of surgery and during the 
follow-up consultations: estradiol (both sexes at the time of surgery), testosterone and SHBG 
(in men), 25(OH)D, calcium, phosphate, creatinine, PTH, NSAIDs treatment (should be 
avoided). If possible; needle biopsies under fluoroscopy of the fracture callus at 2 time-points 
during healing (e.g. 3 and 6 weeks) in selected patients for histology and gene analyses. 
Exclusion criteria: < 40 years, anti-osteoporosis therapy (except for vitamin D and calcium), 
glucocorticoids, anti-convulsives, multitrauma, post-operative infections. 
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ABSTRACT 
TRAP is known as an osteoclast marker, but osteoblasts and osteocytes in the vicinity of bone 
remodeling sites also express TRAP. Cell culture studies suggest that osteoblasts endocytose 
osteoclastic TRAP for inactivation. To evaluate whether changes in osteoclast activity could 
alter TRAP expression in osteoblasts and/or osteocytes in vivo, we studied the ovariectomized 
and vitamin D-deficient rat (Ovx-D), and rats healing from rickets. Bone sections were 
analyzed for TRAP gene expression by in situ hybridization, TRAP protein by immunogold 
labeling and TRAP enzyme activity using the fluorescent substrate ELF97. Osteoblasts and 
osteocytes close to intracortical remodeling sites and bone surfaces demonstrated TRAP, most 
prominent in cancellous bone and in osteocytes. Intracellular TRAP was located to electron 
dense vesicles with similar morphology in both cell types. Ovx-D increased osteoclast activity 
(p<0.001) and ELF97+ osteocytes (p<0.05) in cancellous bone, but no corresponding increase 
was observed in the osteocyte lacunar area. The level of TRAP+ vesicles in cortical 
osteoblasts (p<0.01) in Ovx-D was also increased. Enhanced osteoclast activity was noted in 
healing rickets after 72h (p<0.05), but no differences in TRAP expression were detected in 
osteoblasts or osteocytes. Thus increased osteoclast activity does not affect TRAP expression 
in osteoblast and osteocytes favoring the notion that increased TRAP in these cells is rather 
due to increased synthesis. Although the role of TRAP in osteoblasts and osteocytes remains 
elusive, we speculate that the function is related to the capability of the enzyme to regulate the 
phosphorylation of proteins known to be expressed by these cells.  
Key words: TRAP, Osteoblast, Osteocyte, OVX, Vitamin D 
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INTRODUCTION 
Tartrate-resistant acid phosphatase (TRAP) (ACP5) also known as purple acid phosphatase, 
uteroferrin or type 5 acid phosphatase [1] has been an established marker for osteoclasts and 
bone resorption for more than 50 years. TRAP is synthesized as a relatively inactive pro-
enzyme (monomeric TRAP (mTRAP)/loop-TRAP/serum TRAP 5a) and proteolytic cleavage 
by members of the cathepsin family or other proteinases, increases the catalytic activity at 
least 10-fold [2, 3]. Cleaved, active TRAP is identical to osteoclastic TRAP and serum TRAP 
5b[4] and is able to dephosphorylate bone matrix proteins e.g. osteopontin (OPN) and integrin 
binding sialoprotein (IBSP) [5, 6] as well as to generate reactive oxygen species for bone 
matrix degradation [7]. Halleen and coworkers have shown that the serum activity of TRAP 
5b is significantly elevated in patients with osteoporosis and negatively correlated with bone 
mineral density (BMD) [8]. Studies on mice have yielded similar results: global deletion of 
TRAP leads to disturbed endochondral ossification and a mild osteopetrotic phenotype [9, 
10], while overexpression of TRAP results in enhanced bone turnover and a mild osteoporotic 
phenotype [11]. In addition to osteoclasts, TRAP has also been reported in osteoblasts and 
osteocytes [12-21] closely related to bone surfaces [12, 21] or intracortical remodeling sites 
[12, 16] in rat bone tissue. The origin and function of TRAP in these cells have been debated; 
one hypothesis is that osteoclastic TRAP from the resorption lacunae is endocytosed by the 
osteoblasts and/or osteocytes. This theory is supported by cell culture studies reporting that 
osteoblast-like cells are able to engulf osteoclastic TRAP and inactivate the enzyme, 
suggesting that this could control the enzyme activity and prevent further degradation of 
matrix constituents [17, 18].  However, endogenous TRAP synthesis has been demonstrated 
in osteoblasts [21] and in osteocytes [16] in areas close to bone resorbing osteoclast, 
suggesting that TRAP may take part in mechanisms controlling the direction of osteoclastic 
bone resorption [16]. Qing and co-workers [19] have demonstrated enlarged osteocyte 
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lacunae and canaliculi and increased amount of TRAP and Cathepsin K in osteocytes in 
lactating mice, suggesting that osteocytes are able to remodel their own matrix environment 
through osteoclast-like mechanisms under specific conditions.  
To increase the knowledge of TRAP in osteoblasts and osteocytes, we analyzed two 
experimental rat models with disturbed bone metabolism to investigate whether changes in 
osteoclast activity could alter TRAP protein expression and enzyme activity in osteoblasts 
and/or osteocytes in vivo. The ovariectomized and vitamin D-depleted rat (Ovx-D) mimics 
human osteoporosis as seen in the elderly postmenopausal women with reduced BMD of 
metaphyseal bone [22]. Osteoclast activity and TRAP protein expression in osteoblasts and 
TRAP activity in osteocytes were increased in Ovx-D rats. Moreover, Ovx-D rats presented a 
tendency to increased TRAP mRNA expression in osteocytes, questioning the hypothesis of 
endocytosis being the mechanism enhancing TRAP protein expression and enzyme activity in 
osteoblasts and osteocytes in these rats. To further address this question, rats healing from 
nutritionally induced low phosphate and vitamin D-deficiency rickets (experimental rickets) 
were analyzed as a model of increased osteoclast activity [23]. However, such rats did not 
show any differences in the level of TRAP protein expression or enzyme activity neither in 
osteoblasts nor in osteocytes, making it less likely that osteoblasts and osteocytes endocytose 
osteoclastic TRAP. 
 
MATERIALS AND METHODS 
All analyses were preformed on coded sections using AnalySIS FIVE (Olympus Soft Imaging 
Solutions GmbH, Münster, Germany) following the suggestions for standardized 
nomenclature from ASBMR [24]. 
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Animal experiments  
Guide for the Care and Use of Laboratory Animals [25] was followed and the study protocols 
approved by the Norwegian National Animal Research Authority. The Ovx-D model has been 
reported in detail previously [22]. Low phosphate and vitamin D-deficiency rickets and 
healing for 48h and 72h were induced as described by Hollberg et al 2005 [23]. Blood was 
sampled from the animals and their tissues fixed by vascular perfusion [22] at the end of the 
experiments.  
 
Tissue preparation 
Femurs and tibias were dissected free, immersed in 2% phosphate-buffered paraformaldehyde 
and decalcified in 7% EDTA with 0.5% paraformaldehyde for 40 days. Bone tissues for light 
microscopy or fluorescence microscopy were paraffin-embedded and 2-3μm thick sections 
were cut, picked up on glass-slides and rehydrated in series of graded alcohols. Bone tissues 
for transmission electron microscopy (TEM) were cut into small samples (~1 mm3), fixed in 
2% paraformaldehyde and 0.5% glutaraldehyde and embedded with progressive lowering of 
temperature (Leica EM AFS, Leica Microsystems AG, Wetzlar, Germany) in the acrylate- 
and methacrylate-based resin Lowicryl HM23 according to our established protocol [26]. 
Ultrathin sections (75 nm) were mounted on formvar-coated nickel slot grids. 
 
Osteoclast activity 
Total number of osteoclasts relative to tissue volume (N.Oc/TV) and osteoclasts surface 
relative to bone surface (Oc.S/BS) were estimated by point counting in a squared grid within 
500μm from EMB at TEM micrographs. An osteoclast was defined as a multinuclear cell 
attached to bone surface or in the intertrabecular space with characteristics such as ruffled 
border, intracytoplasmic vesicles and abundant mitochondrial profiles. Twenty micrographs 
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from each animal were analyzed and the ratio (Oc.S/BS)/(N.Oc/TV) calculated for each 
animal and compared between Ovx-D and sham as a parameter of osteoclast activity [27]. In 
the experimental rickets group, commercially available kits were used for determination of 
osteoclast-derived C-telopeptide fragments of collagen type I (CTX) (RatLaps™ EIA, 
Immunodiagnostic Systems Ltd., Tyne & Wear, UK) and osteoclast derived TRAP 5b 
(RatTRAP™ Assay, Immunodiagnostic Systems Ltd., Tyne & Wear, UK). Serum was 
analyzed in all animals and the results of the CTX/TRAP 5b ratio, as a parameter for 
osteoclast activity [27], calculated for each animal and compared between the groups. 
 
In situ hybridization 
TRAP gene expression was studied by in situ hybridization. A gene sequence for rat TRAP 
[28] was amplified by conventional PCR using cDNA from rat bone and oligonucleotide 
forward and reverse primers; rnTRAP.for 5’-ACGCCAATGACAAGAGGT TC-3’, 
rnTRAP.rev 5’-ACATAGCCCACACCGTTCTC-3’(Life Technologies Co., Carlsbad, CA, 
USA) and cloned in a Dual Promoter TA Cloning Kit (Life Technologies Co., Carlsbad, CA, 
USA). The cloned insert was sequenced to establish the orientation (Seqlab, Göttingen, 
Germany). A digoxigenin (DIG)-conjugated complementary RNA probe was synthesized 
using T7 or Sp6 polymerase to yield the probe in the sense or antisense direction (DIG-
labeling kit, Roche Diagnostics AS, Oslo, Norway). Longitudinal sections from tibia 
diaphysis (Ovx-D/sham) and femur diaphysis (experimental rickets) were subjected to 
hybridization following our established protocol [29]. TRAP mRNA+ osteocytes were 
quantified in cortical bone within 4-10 mm from the proximal epiphyseal/metaphyseal border 
(EBM) by point counting in a squared grid. Three sections were examined from each animal 
and their means compared between the groups. The tibia diaphyses were examined twice with 
interclass correlation of p<0.001, and Cronbach’s alfa of 0.94. Staining of osteoclasts from 
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femur metaphysis in healing for 72h were used as positive control. The sense probe did not 
show any staining.  
 
Immunofluorescence  
To estimate TRAP enzyme activity and the putative co-localization of the translated 
monomeric TRAP protein (mTRAP) and the enzyme activity, fluorescence based staining 
with rabbit anti-mTRAP and ELF97 was performed. With low pH (<6.0) ELF97 is cleaved by 
activated acid phosphatase yielding a bright yellow-green-fluorescence precipitate [30, 31]. 
Rabbit anti-mTRAP was the same as previously used [32]. ELF97 Endogenous Phosphatase 
Detection kit, AlexaFlour555 conjugated secondary antibody and DAPI Nucleic Acid Stain 
were purchased from Molecular Probes (Invitrogen Co., Eugene, OR, USA). Longitudinal 
sections from distal femur metaphysis and diaphysis were analyzed. Images were obtained by 
Nikon DS-Fi2 color camera (Nikon Instruments Inc., Melville, NY, USA) using UV and Cy3 
filters and added in ImageJ [33]. ELF97+ osteocytes (Ot), mTRAP+ Ot, ELF97mTRAP+ Ot 
and total Ot were quantified in cancellous bone within 1 mm into the metaphysis from the 
proximal EMB and in cortical bone within 4-10 mm from the proximal EMB. The means 
were calculated for each animal with respect to the parameters above and used for comparison 
between the groups. Non-specific rabbit IgG served as negative control for mTRAP, while 
TRAP enzyme activity was inactivated using 100μM molybdate before adding ELF97 to 
evaluate the background fluorescence. 
 
Immunogold labeling for TEM 
To evaluate the distribution of TRAP in osteoblasts and osteocytes, bone sections from tibia 
diaphysis (Ovx-D/sham) and proximal tibia metaphysis and diaphysis (experimental rickets) 
were labeled with rabbit anti-TRAP (SB-TR103, Immunodiagnostic Systems Ltd., Tyne & 
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Wear, UK). The immunogold labeling was performed as earlier described [34]. Non-specific 
rabbit-IgG served as negative control. Micrographs of 10-20 osteoblasts; defined as 
mononuclear cells attached to osteoid or bone matrix with prominent ER and Golgi 
complexes, and osteocytes; defined as mononuclear cells embedded in bone matrix with 
characteristic canaliculi, were randomly sampled from each animal. TRAP+ vesicle was 
defined as a vesicle of moderate electron density containing >4 gold particles. Area of 
TRAP+ vesicles (TRAPv.Ar) relative to the area of cytoplasm (Cy.Ar) was measured in each 
osteoblast and osteocyte and the mean of the ratios (TRAPv.Ar/Cy.Ar) for each animal 
compared between the groups. The cells were analyzed twice with respect to 
TRAPv.Ar/Cy.Ar with interclass correlation of p<0.001, and Cronbach’s alfa of 0.98. Large 
standard deviations (SDs) in the ratios were observed for both osteoblasts and osteocytes 
within the Ovx-D and sham. To elucidate whether this phenomenon was due to differences 
between the animals in each group or in each animal, 8 bone levels in one animal from each 
group were examined. The results displayed that the large SDs between the animals 
corresponded to the SDs between bone levels in each animal, indicating large biological 
variation (data not shown).  
 
Osteocyte lacunar area  
Longitudinal tibia mid-diaphyseal sections from Ovx-D and sham at the same bone level were 
subjected to conventional hematoxylin-eosin-saffron (HES) staining. The osteocyte lacunar 
area was measured within 1 mm at 3 discrete sites separated by 1 mm in a cross-sectional 
manner. Both cortices were included and 200-250 osteocytes were measured per animal. The 
means of the osteocyte lacunar area were calculated and compared between the groups.  
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Statistics  
The statistical analyses were performed in PASW Statistics 18 (SPSS Inc., Chicago, IL, 
USA). Parametric tests were used to compare the measured data; Student’s t-test for two 
variables and one-way analyses of variance (ANOVA) for k variables. Nonparametric tests; 
Mann-Whitney for two variables and Kruskal-Wallis for k variables, were applied on the 
semi-quantitative data. A p-value of 0.05 was considered significant in all tests. 
 
RESULTS 
Animal models  
The Ovx-D rats developed osteoporosis with reduced trabecular bone volume (BV/TV) in the 
femur head, p<0.001, and decreased BMD in the femur neck and the lower lumbar vertebra, 
p<0.001, (Online Resource 1a, b) as well as undetectable serum levels of 25(OH)D and serum 
estradiol within the human postmenopausal range [22]. Low phosphate and vitamin D 
deficiency induced rickets with characteristic morphological changes (Online Resource 1c) 
were in line with previous experience with the model [23]. 
 
Enhanced osteoclast activity in the animal models 
To be able to evaluate TRAP positivity in osteocytes and osteoblasts in relation to osteoclast 
activity, we calculated osteoclast activity as Oc.S/BS relative to N.Oc/TV and CTX relative to 
TRAP 5b in serum in Ovx-D/sham and experimental rickets, respectively. Increased 
osteoclast activity was observed in Ovx-D vs. sham (Fig. 1a), as well as in healing rickets 
after 72h compared to fulminant rickets and normal controls reflecting the healing of the 
growth plate with enhanced resorption monitored by an increased CTX/TRAP 5b ratio in 
serum (Fig. 1b).  
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TRAP is increased in osteoblasts and osteocytes in Ovx-D 
In cancellous bone ELF97+Ot/Ot and co-localized ELF97mTRAP+Ot/Ot were increased in 
Ovx-D vs. sham (Fig. 2, Fig. 3a). Ovx-D also demonstrated a tendency to increase in 
ELF97+Ot/Ot and ELF97mTRAP+Ot/Ot vs. sham in cortical bone (Online Resource 2, Fig. 
3b). TEM analyses showed TRAP in intracellular electron dense vesicles (200-500nm in 
diameter) with similar morphological features in both osteoblasts and osteocytes in cortical 
bone. However, no general pattern of location in the cytoplasm was detected and we were not 
able to demonstrate any fusion between TRAP+ vesicles and the cell-membrane, or any 
coated pits at the cell-surface containing TRAP (Fig. 4a-h). Semi-quantitative measurements 
of the area of TRAP+ vesicles relative to total cytoplasmic area (TRAPv.Ar/Cy.Ar) showed 
an increased ratio in osteoblasts and osteocytes in Ovx-D compared with sham, significant in 
osteoblasts (Fig. 4i). In situ hybridization demonstrated TRAP mRNA in osteocytes in 
cortical bone close to intracortical remodeling sites and bone surfaces in both Ovx-D and 
sham (Fig. 5a-c), however, only a small proportion of the osteocytes in cortical bone were 
TRAP mRNA+: 2.9% in Ovx-D vs. 0.09% in sham. Although the difference appeared 
striking, the result was not statistically significant (Fig. 5e). 
 
Healing from rickets does not alter TRAP in osteoblasts or osteocytes  
No difference was detected in TRAP enzyme activity (ELF97+Ot/Ot), mTRAP+Ot/Ot or 
ELF97mTRAP+Ot/Ot in neither cancellous nor cortical bone in any of the groups in the 
experimental rickets model (Fig. 6). The TRAP+ vesicles were observed in both osteoblasts 
and osteocytes in cancellous bone and presented similar features as in osteoblasts and 
osteocytes in the experimental osteoporosis model. However, there was no difference in the 
ratio TRAPv.Ar/Cy.Ar between the groups. In cortical bone only a few TRAP+ vesicles were 
observed in osteocytes and none in osteoblasts. TRAP mRNA in situ hybridization in femur 
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diaphysis failed to demonstrate TRAP mRNA+ osteocytes in any of the groups, despite 
staining in the metaphyseal osteoclasts used as positive controls (data not shown) and with no 
staining for the sense probe.  
 
TRAP+ vesicles are more abundant in osteocytes compared with osteoblasts 
TEM revealed increased TRAPv.Ar/Cy.Ar ratio in osteocytes vs. osteoblasts in cancellous 
bone for the animals in the experimental rickets model, p<0.05 (rickets and controls), p<0.01 
(healing after 48h), (Online Resource 3a). In cortical bone osteocytes from the Ovx-D and 
sham rats also demonstrated increased TRAPv.Ar/Cy.Ar ratio vs. osteoblasts, significant in 
sham, p<0.001 (Online Resource 3b). Only a small number of TRAP+ vesicles were detected 
in cortical osteocytes and none in cortical osteoblasts in the experimental rickets model. 
 
TRAP activity in osteoblasts and osteocytes is most prominent in cancellous bone  
TRAP enzyme activity in osteocytes (ELF97+Ot/Ot) was increased in cancellous vs. cortical 
bone in all groups from both animal models, p<0.01 (Ovx-D, sham, rickets, healing after 48h 
and controls), p<0.05 (healing after 72h), (Online Resource 4a). The vesicle ratio 
TRAPv.Ar/Cy.Ar was increased in cancellous vs. cortical bone in osteoblasts and osteocytes 
in all animals in the experimental rickets groups; Ot: p<0.001 (rickets and healing after 48h), 
p<0.05 (healing after 72h), p<0.01 (controls); Ob: p<0.001 (rickets, healing after 48h and 
controls), p<0.01 (healing after 72h) (Online Resource 4b, c). 
 
No difference in osteocyte lacunar area in cortical bone in Ovx-D vs. sham  
To elucidate whether the increased level of TRAP in osteocytes in Ovx-D could be related to 
increased local resorption as described for lactating mice [19], osteocyte lacunar area in 
cortical bone was measured, but no difference was detected between the groups (Fig. 7).  
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DISCUSSION 
Osteoclastic TRAP has been demonstrated in transcytotic intracellular vesicles as well as in 
the ruffled border beneath the osteoclast during active bone resorption [7, 23, 29, 35, 36]. The 
secretion of TRAP from the osteoclast to the resorption lacuna makes TRAP available for 
other bone cells and TRAP has been suggested as one of the “coupling-factors” between bone 
resorption and bone formation [37]. Previous studies have demonstrated TRAP in osteoblasts 
and osteocytes in areas close to active bone resorption sites [12, 16, 21], which has led to the 
hypothesis that osteoblasts and/or osteocytes engulf osteoclastic TRAP for inactivation [17]. 
We tested this hypothesis in vivo by analyzing TRAP expression in osteoblasts and osteocytes 
in two animal models with increased osteoclast activity; the experimental osteoporotic rat and 
rats healing from dietary induced rickets. In both models osteocytes and osteoblasts in 
cancellous bone and in cortical bone close to intracortical remodeling sites and 
endosteal/periosteal surfaces demonstrated TRAP gene expression and translation to protein 
as well as TRAP enzyme activity, which are in line with former observations. TEM analyzes 
revealed TRAP in intracellular vesicles with identical morphological features in osteoblasts 
and osteocytes in all the animals in both experimental models. This observation indicate that 
TRAP in osteoblasts and osteocytes might be located to endosomes, involved in intracellular 
transport or stored in vesicular compartments for secretion. Moreover, the Ovx-D group 
demonstrated an increased ratio of TRAP+ vesicles in osteoblasts in cortical bone and 
increased TRAP enzyme activity in osteocytes in cancellous bone, and we also observed a 
tendency to enhanced levels of TRAP gene expression in osteocytes in cortical bone. These 
results indicate that the observed increase in TRAP protein expression and enzyme activity in 
osteoblasts and osteocytes is due to increased synthesis and not increased osteoclast activity. 
Moreover, no changes were demonstrated between the animals in the different groups in the 
experimental rickets model regarding TRAP in osteoblasts and osteocytes, despite the 
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increased osteoclast activity in rats healing for 72h. Thus, enhanced osteoclast activity does 
not change TRAP expression in vivo in osteoblasts or osteocytes in our models. Consequently, 
TRAP observed in osteoblasts and osteocytes is not engulfed osteoclastic TRAP but rather 
synthesized in the respective cells. The theory of osteoblast and osteocyte endocytosis of 
osteoclastic TRAP[17] is therefore not supported by our results. A similar conclusion has 
been drawn by Bonucci and co-workers [13]: they observed that the increased level of TRAP 
positive osteoblasts in calcium depleted rats returned to normal when calcium was repleted 
despite unchanged levels of TRAP positive osteoclasts.  
Comparison of TRAP expression in cancellous vs. cortical bone demonstrated 
enhanced levels of TRAP enzyme activity in osteocytes in all animal groups as well as an 
increase in the ratio of TRAP+ vesicles in osteoblasts and osteocytes in the animals in the 
experimental rickets groups. There is an obvious structural difference between cancellous and 
cortical bone and cancellous bone appears to be more metabolic active than cortical bone with 
a higher bone turnover. This might be explained by a greater surface to volume ratio in 
cancellous vs. cortical bone [38]. The increase in TRAP+ vesicles and enzyme activity in 
osteoblasts and osteocytes in cancellous bone might therefore be linked to bone turnover, 
however the mechanism remains elusive. 
Qing and co-workers observed increased TRAP as well as cathepsin K in osteocytes in 
lactating mice [19] with a corresponding increase in the osteocyte lacunar area. In a recent 
study Kogawa and co-workers [39] show that sclerostin increases the expression of TRAP, 
cathepsin K and carbonic anhydrase (CA2) in osteocytes with a resulting increase in the 
osteocyte lacunar area. The effect is reversed by the CA2 inhibitor acetozolamide, which 
indicates that the osteocytic osteolysis is at least partly dependent on CA2 and its response to 
sclerostin. However, the effects by inhibition of TRAP or cathepsin K on the osteocyte 
lacunar area were not reported. Taken together, both lactation and sclerostin seem to enhance 
14 
 
TRAP expression in osteocytes as well as the ostocytic osteolysis. We investigated the effect 
of TRAP on the osteocytic osteolysis in the experimental osteoporosis model, but failed to 
demonstrate any difference in the osteocyte lacunar area between Ovx-D and sham despite 
increased osteocytic TRAP in the Ovx-D animals. An explanation for this may be that we did 
our measurements on decalcified tissue sections. However, this method has been used by 
others with success [39]. Consequently, we propose that osteocytic TRAP is not solely related 
to osteocytic osteolysis but has an additional role in osteocytes. Our TEM observations of 
TRAP located to intracellular vesicles with similar morphological features in both osteoblasts 
and osteocytes indicate that TRAP may have corresponding functions in the two cell types. 
Moreover, osteoblasts do not normally dissolve bone mineral and the observed increase in 
osteoblastic TRAP in the Ovx-D animals is therefore unlikely to be related to local mineral 
handling by the osteoblasts. In conclusion, the role of TRAP in osteoblasts and osteocytes still 
remains elusive. However, our results support the notion that TRAP may have another not yet 
clarified role in osteocytes, in addition to the suggested contribution in local mineral handling. 
It is proposed that the function of TRAP in osteoblasts and osteocytes involves the capability 
of the enzyme to regulate phosphorylation of proteins known to be expressed by these cells 
such as DMP1, MEPE and FGF23.  
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FIGURES 
 
 
 
Fig. 1 Osteoclast activity 
a The ratio of (Oc.S/BS)/(N.Oc/TV) in cancellous bone was increased in Ovx-D vs. sham 
(Student’s t-test, n=7/7). b The ratio of serum CTX/TRAP 5b was increased in healing for 
72h compared with fulminant rickets (R) and controls (C) (ANOVA, n=7/7/7/7). aThe results 
are presented with mean and SD, * p<0.05, *** p<0.001 
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Fig. 2 TRAP enzyme activity and monomeric TRAP (mTRAP) immunolabeling in osteocytes 
(Ot) in cancellous bone from distal femur metaphysis a HES stained sections show the tissue 
architecture of cancellous bone in sham and e Ovx-D. The black outlines demonstrate 
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corresponding areas to the immunofluorescence images. b-d ELF97+ Ot (yellow-green, 
arrows), mTRAP+ Ot (red) and ELF97mTRAP+ Ot (arrowheads) in sham and f-h Ovx-D. i 
Inhibition of TRAP enzyme activity with molybdate demonstrated low background 
fluorescence for ELF97. j Unspecific rabbit IgG served as negative control for mTRAP with 
low background fluorescence. k A high power image shows the staining of ELF97 and 
mTRAP in the osteocytes. Scalebars 10μm 
 
 
 
Fig. 3 TRAP enzyme activity in osteocytes in cancellous and cortical bone in the 
experimental osteoporosis model a ELF97+ Ot/Ot and ELF97mTRAP+ Ot/Ot were 
significantly increased in Ovx-D vs. sham in cancellous bone, b while there were no 
significant differences between the groups in cortical bone (Mann-Whitney test, n=7/7). aThe 
results are presented with mean and SD, * p<0.05 
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Fig. 4 TEM micrographs from tibia diaphysis in Ovx-D and sham. The images with overview 
and close-ups show examples of immunogold labeling for TRAP in intracellular vesicles in 
osteoblasts (Ob) and osteocytes (Ot) in cortical bone; a, b Osteocyte and c, d osteoblast from 
Ovx-D and e, f osteocyte from sham with TRAP+ vesicles. g, h Unspecific rabbit-IgG served 
as negative control and did not label the vesicles in Ovx-D. i Significantly increased TRAP 
vesicle area vs. area of cytoplasm (TRAPv.Ar/Cy.Ar) ratio in osteoblasts in Ovx-D vs. sham 
(Mann-Whitney test, n=7/7). aThe results are presented with mean and SD, ** p<0.01  
23 
 
 
Fig. 5 In situ hybridization for TRAP mRNA in tibia diaphysis in Ovx-D and sham animals. a 
TRAP mRNA positive osteocytes (Ot) (arrows) were stained dark blue and observed closely 
related to the bone surface (BS) and the bone remodeling surface (Rm.S) in Ovx-D. b Sham 
animals demonstrated a limited number of TRAP mRNA positive osteocytes (arrows) c The 
method was confirmed by positive staining of an osteoclast in a bone morphogenic unit 
(BMU) with TRAP mRNA positive osteocytes (arrows) within close vicinity (Ovx-D). (The 
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asterisk marks a central capillary.) d The sense-probe displayed no staining and served as a 
negative control. e There was no significant difference in TRAPmRNA+Ot/ Ot between Ovx-
D and sham (Mann-Whitney test, n=7/7). aThe results are presented with mean and SD  
 
 
 
 
Fig. 6 TRAP enzyme activity in osteocytes (Ot) a cancellous and b cortical bone in the 
experimental rickets model demonstrated no significant differences between the groups; 
fulminant rickets (R), healing for 48h, healing for 72h and controls (C) (Kruskali-Wallis test, 
n=7/7/7/7). aThe results are presented with mean and SD  
 
 
25 
 
 
Fig. 7 a Cortical bone sections (tibia diaphyses) from Ovx-D and sham were formalin fixed, 
paraffin embedded and cut in 3μm thick sections before conventional hematoxylin-eosin-
saffron staining was performed. A clear definition of the osteocyte lancunar outline was 
obtained after staining of the tissue sections for both Ovx-D and sham. This is demonstrated 
by the high power images inserted. b There was no difference in the osteocyte (Ot) lacunar 
area between Ovx-D and sham (Student’s t-test, n=7/7). aThe results are presented with mean 
and SD  
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ONLINE RESOURCES 
 
Online Resource 1 Animal models a Light microscopic images display a large difference in 
trabecular bone volume (BV/TV) between Ovx-D and sham. b BV/TV in femoral head and 
bone mineral density (BMD) in femoral neck and vertebrae were decreased in Ovx-D vs. 
sham (Student’s t-test, n=7/7). c The animals with fulminant rickets demonstrated enlarged 
physis/metaphysis and lack of well-defined EMB, while a healing zone (He.Z) had developed 
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at 48h healing.  After healing for 72h the animals showed almost a normal structure at the 
EMB but still with a small He.Z compared to controls. aThe results are presented with mean 
and SD, bThe results are means of the right and left limb, *** p<0.001 
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Online Resource 2 TRAP enzyme activity and monomeric TRAP (mTRAP) immunolabeling 
in osteocytes (Ot) in cortical bone from femur diaphysis. a HES stained sections of cortical 
bone in sham and e Ovx-D show the tissue architecture. The black outlines demonstrate 
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corresponding areas to the immunofluorescence images. b-d ELF97+ Ot (yellow-green, 
arrows), mTRAP+ Ot (red) and ELF97mTRAP+ Ot (arrowheads) in sham and f-h Ovx-D. i 
Inhibition of TRAP enzyme activity with molybdate demonstrated low background 
fluorescence for ELF97. j Unspecific rabbit IgG served as negative control for mTRAP with 
low background fluorescence. Scalebars 10μm 
 
 
 
Online Resource 3 Histomorphometric semi-quantitative analyses of TRAPv.Ar/Cy.Ar in 
osteocytes (Ot) and osteoblasts (Ob). a TRAPv.Ar/Cy.Ar Ot vs. Ob in cancellous bone in 
experimental rickets (n=7/7/6/7). b TRAPv.Ar/Cy.Ar Ot vs. Ob in cortical bone in all groups 
(n=7/7/7/7/5/6) (b). The statistical analyses are performed with Mann-Whitney test. aThe 
results are presented with mean and SD, ** p<0.01, *** p<0.001 
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Online Resource 4 TRAP expression increased in osteocytes (Ot) and osteoblasts (Ob) in 
cancellous vs. cortical bone. a TRAP enzyme activity in all groups displayed by 
ELF97+Ot/Ot. b TRAPv.Ar/Cy.Ar in Ot in experimental rickets. c TRAPv.Ar/Cy.Ar in Ob in 
experimental rickets. The statistical analyses are performed with Mann-Whitney test. aThe 
results are presented with mean and SD, * p<0.05, ** p<0.01, *** p<0.001 
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